Payload ID	PAY0SJUSE
Name	Undisclosed
Synonyms	Undisclosed    Click to Show/Hide
Target	Stimulator of interferon genes protein (STING1)					Target Info

Experiment 1 Reporting the Activity Date of This ADC					[1]
Patients Enrolled	Eligible subjects must be ≥18 years with measurable disease (RECIST 1.1), ECOG 0-1, and adequate organ function. Key exclusions include recent antitumor therapy (within 4 weeks/5 half-lives), prior topoisomerase I inhibitor ADC failure, planned antitumor therapy during study, or symptomatic CNS metastases.
Administration Dosage	Subjects will receive IBI129 on Day 1 of a 21-day cycle (or intervals determined by the Investigator and Sponsor based on safety, toxicity and PK data), until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.    Click to Show/Hide
Related Clinical Trial
NCT Number	NCT05991349	Phase Status	PHASE1|||PHASE2
Clinical Description	A Phase 1/2 Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors
Primary Endpoint	The study evaluates safety through adverse events (NCI CTCAE v5.0), physical exams, vital signs, and determines MTD/RP2D of IBI129 over 12-24 months.
Other Endpoint	Pharmacokinetic parameters (Cmax, AUC, Tmax, CL, V, T1/2) and immunogenicity of IBI129 are assessed over 12 months, while efficacy endpoints (ORR, DoR, DCR, TTR, PFS, OS) follow RECIST v1.1 criteria over 24 months.

Experiment 1 Reporting the Activity Date of This ADC					[2]
Patients Enrolled	Eligible subjects must be ≥18 years with advanced solid tumors (RECIST 1.1 measurable), ECOG 0-1, and adequate organ function. Key exclusions include cardiac dysfunction (NYHA II-IV, recent MI/unstable angina), active autoimmune/inflammatory diseases, uncontrolled infections, HIV/HBV/HCV, pregnancy/lactation, or unwillingness to use contraception.    Click to Show/Hide
Administration Dosage	Enrolled Subjects will receive a single-dose of DB-1202 at Dose Level 1 on Day 1 of each cycle Q3W
Related Clinical Trial
NCT Number	NCT05785728	Phase Status	PHASE1|||PHASE2
Clinical Description	Phase 1/2, Multicenter, Open-label, First-in-human Study of DB-1202 Monotherapy in Patients With Advanced Solid Malignant Tumors to Evaluate the Tolerability, Safety, Pharmacokinetics and Antitumor Activity
Primary Endpoint	The study evaluates safety through DLTs (21 days post-Cycle 1), TEAEs/SAEs (CTCAE v5.0) over 1 year, and determines MTD/RP2D of DB-1202 in Phase 1, while Phase 2a assesses TEAEs/SAEs and ORR (RECIST 1.1) over 1 year.
Other Endpoint	Pharmacokinetic parameters (AUC, Cmax, Tmax, T1/2) of DB-1202 are analyzed within 8 treatment cycles (21-day cycles) across both Phase 1 and Phase 2a.
Experiment 2 Reporting the Activity Date of This ADC					[3]
Related Clinical Trial
NCT Number	NCT05785728	Phase Status	Phase 1/2
Clinical Description	Phase 1/2, multicenter, open-label, first-in-human study of DB-1202 monotherapy in patients with advanced solid malignant tumors to evaluate the tolerability, safety, pharmacokinetics and antitumor activity.

Experiment 1 Reporting the Activity Date of This ADC					[4]
Patients Enrolled	Adults (≥18) with histologically confirmed pancreatic/bladder/GI tumors or imaging-suspected PDAC
Administration Dosage	On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
Related Clinical Trial
NCT Number	NCT05737615	Phase Status	PHASE1
Clinical Description	A Phase I Study of Pretargeted PET Imaging Using 64Cu-Tz-SarAr and a Trans-Cyclooctene-Modified Humanized 5B1 Immunoconjugate (hu5B1-TCO) in Patients With Pancreatic, Bladder Cancer, Gastrointestinal Malignancies or Solid Tumors With Elevated CA19-9
Primary Endpoint	Primary endpoint is SUV mean measurement across multiple organs (heart, liver, spleen, kidney, lung, and other uptake sites) [Time Frame: 28 months].

Experiment 1 Reporting the Activity Date of This ADC					[5]
Patients Enrolled	Key eligibility comprises Phase 1a patients with advanced mCRPC/GC/NSCLC and Phase 1b with castration-resistant prostate cancer (testosterone <50ng/dL) failing SOC therapies, requiring measurable disease (RECIST 1.1 or PCWG3) and ECOG 0-1/0-2 status. Major exclusions include active CNS metastases, significant CVD, recent malignancies (<3 years), current ILD/pneumonitis, or active infections (prophylaxis allowed).    Click to Show/Hide
Administration Dosage	Increasing doses of ADRX-0405 will be administered to identify the maximum tolerated dose (MTD) and the recommended dose to be used in the Phase 1b part.
Related Clinical Trial
NCT Number	NCT06710379	Phase Status	PHASE1
Clinical Description	A Phase 1a/b Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors
Primary Endpoint	Primary safety evaluation focuses on adverse event monitoring throughout the 2-year study period for ADRX-0405 in advanced solid tumors including mCRPC, GC, and NSCLC, particularly in treatment-resistant mCRPC cases.
Other Endpoint	econdary assessments include comprehensive PK profiling (Ceoi/Cmax, Ctrough, AUC, t1/2, CL, Vss), immunogenicity (ADA incidence), and efficacy metrics (ORR by RECIST 1.1/PCWG3, DOR, DCR, PFS, rPFS, OS) all measured over the 2-year study duration.

Experiment 1 Reporting the Activity Date of This ADC					[6]
Patients Enrolled	Inclusion: Signed consent, age ≥18, ECOG 0-2 (lymphoma) or 0-1 (solid tumors), life expectancy ≥3 months, measurable lesions, adequate organ function, contraception use. Exclusion: CNS/brain metastases, GVHD ≥G2, active infections, uncontrolled effusions, severe comorbidities, pregnancy, or conditions compromising study integrity per investigator judgment.    Click to Show/Hide
Administration Dosage	In dose escalation phase, participants will be administered escalating doses of HDM2005 at 0.3~2.75mg/kg IV on Day 1 of repeated 21-day cycles. In dose expansion phase, participants will be administered to recommended dose for expansion (RDE) of HDM2005 on Day 1 of repeated 21-day cycles .
Related Clinical Trial
NCT Number	NCT06615193	Phase Status	PHASE1
Clinical Description	A Phase Ia/Ib, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Primary Endpoint	The dose escalation phase evaluates DLT incidence (21-day post-first dose) and AE severity (28-day post-last dose) per NCI CTCAE v5.0. The expansion phase assesses ORR (CR/PR, up to 3.5 years) and RP2D determination based on safety, PK, exposure-response, and efficacy data.
Other Endpoint	Pharmacokinetics include plasma concentrations of HDM2005, total antibody, and free MMAE (28-day post-last dose). Immunogenicity measures ADA-positive patients. Safety (AE monitoring) and efficacy endpoints (ORR, TTR, PFS, DOR, OS) are tracked for both phases over ~3.5 years.

Experiment 1 Reporting the Activity Date of This ADC					[7]
Patients Enrolled	Eligible patients must be ≥18 years with ECOG ≤2; Phase 1a requires advanced epithelial solid tumors (failed prior chemo), Phase 1b requires recurrent/metastatic gastric cancer (chemo-naïve or failed prior chemo), with adequate organ function and life expectancy ≥3 months. Exclusions include CNS metastases, recent chemo/radiation/surgery, active infections, uncontrolled diabetes, significant cardiac history, or concurrent investigational therapies.    Click to Show/Hide
Administration Dosage	Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks; Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Related Clinical Trial
NCT Number	NCT01466569	Phase Status	PHASE1
Clinical Description	A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors
Primary Endpoint	Safety evaluation includes adverse events (AEs), clinical lab tests, and physical exams over 10 weeks, focusing on treatment-emergent AEs and their severity.
Other Endpoint	Pharmacokinetic analysis at 3 dose levels (Phase 1a) and 2 dose levels (Phase 1b), with immunogenicity assessment (anti-drug antibodies) and tumor response per RECIST criteria, monitored over 10-12 weeks

Experiment 1 Reporting the Activity Date of This ADC					[8]
Patients Enrolled	Inclusion: Adults (≥18y) with CD20+ indolent B-cell NHL (follicular, MALT, or marginal zone lymphoma), measurable lesions (>1.5cm), ECOG 0-2, adequate organ function, and contraception use. Exclusion: Prior MAb therapy (3 months), active infections, CNS involvement, severe cardiovascular/neuropathic conditions, HIV/HBV/HCV positivity, pregnancy, or uncontrolled comorbidities per investigator judgment.    Click to Show/Hide
Administration Dosage	Dosage: 125 mg/m2, 250 mg/m2, 375 mg/m2 and 500 mg/m2. Formulation: concentrate for preparation of infusions 500 mg/50 ml and 100 mg/10 ml.Mode of administration: intravenous.
Related Clinical Trial
NCT Number	NCT03057418	Phase Status	PHASE1
Clinical Description	Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Aurixim Multiple Doses in Patients With Recurrent/Refractory B-cell, CD20-positive Non-Hodgkin Lymphoma of Low Tumor Grade or With Follicular Lymphoma
Primary Endpoint	The study evaluates treatment-emergent adverse events (AEs) and determines the maximum tolerated dose (MTD) of Aurixim over 24 weeks. Safety assessments include CTCAE-graded AEs, lab abnormalities, and ECG findings. MTD is defined as the highest dose where ≤1/6 patients experience dose-limiting toxicities (DLTs) within 36 days.
Other Endpoint	Pharmacokinetic (AUC, Cmax, T1/2) and pharmacodynamic (CD19+ levels) analyses will be conducted up to week 71 after single/multiple Aurixim doses to characterize drug exposure and biological effects.
Experiment 2 Reporting the Activity Date of This ADC					[10]
Related Clinical Trial
NCT Number	NCT03057418	Phase Status	Phase 1
Clinical Description	Open-label study of safety, tolerability, pharmacokinetics and pharmacodynamics of auriim multiple doses in patients with recurrent/refractory -cell, CD20-positive non-hodgkin lymphoma of low tumor grade or with follicular lymphoma.

Experiment 1 Reporting the Activity Date of This ADC					[9]
Patients Enrolled	Eligibility: HER2+ (IHC3+/ISH+) metastatic breast cancer patients (≥18y, ECOG 0-2) progressing post-trastuzumab, with adequate organ function (ANC ≥1.5×109/L, platelets ≥100×109/L, LVEF >50%). Exclusion: Significant cardiac disease, CNS metastases, prior trastuzumab hypersensitivity ≥G3, recent anticancer therapy (<4 weeks), HIV/HCV/HBV infection, pregnancy, or investigator-assessed safety concerns.    Click to Show/Hide
Administration Dosage	BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
Related Clinical Trial
NCT Number	NCT03062007	Phase Status	PHASE1
Clinical Description	Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab
Primary Endpoint	The study evaluates treatment-emergent AEs (CTCAE-graded) and determines MTD/RD of BI-CON-02 over 55 weeks, with MTD defined as the highest dose where ≤1/6 patients experience DLTs by Week 3 Day 1, including lab abnormalities and ECG findings.
Other Endpoint	PK parameters (AUC, Cmax, T1/2, Vss, CL) and immunogenicity (anti-BI-CON-02 antibodies) will be analyzed up to 55 weeks to characterize drug exposure and immune response.
Experiment 2 Reporting the Activity Date of This ADC					[11]
Related Clinical Trial
NCT Number	NCT03062007	Phase Status	Phase 1
Clinical Description	Open-label study of safety, tolerability and pharmacokinetics of multiple doses of BI-CON-02 in patients with HER2-positive metastatic breast cancer, previously treated with trastuzumab.

Experiment 1 Reporting the Activity Date of This ADC					[12]
Patients Enrolled	Patients with advanced solid tumors confirmed histologically or cytologically must have received standard treatment, have not responded to standard treatment, or have been intolerant to standard treatment, including, but not limited to, triple-negative breast cancer, cervical cancer, endometrial cancer, ovarian cancer, uroepithelial cancer, pancreatic cancer, esophageal cancer, and non-small cell lung cancer. Triple-negative breast cancer, cervical cancer, ovarian cancer and urothelial carcinoma were included in the dose expansion phase.    Click to Show/Hide
Related Clinical Trial
NCT Number	CTR20231203	Phase Status	Phase 1/2
Clinical Description	An open, multicenter Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic profile and initial efficacy of XYD-9668-198 antibody coupling agent in patients with advanced solid tumors

Experiment 1 Reporting the Activity Date of This ADC					[13]
Patients Enrolled	This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
Related Clinical Trial
NCT Number	NCT05365659	Phase Status	Phase 1
Clinical Description	This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Negative FAP expression (FAP-)
Method Description	Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
In Vivo Model	Pancreatic adenocarcinoma PDX model (PDX: PAXF-736)
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Negative FAP expression (FAP-)
Method Description	Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
In Vivo Model	Pancreatic adenocarcinoma PDX model (PDX: PAXF-736)

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.6 nM	Positive FAP expression (FAP+++/++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Fibrosarcoma	HT-1080 cells (FAP expression)		CVCL_0317
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.33 nM	Negative FAP expression (FAP-)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Fibrosarcoma	HT-1080 cells (FAP expression)		CVCL_0317

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Negative FAP expression (FAP-)
Method Description	Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
In Vivo Model	Pancreatic adenocarcinoma PDX model (PDX: PAXF-736)

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	552 nM	Negative FAP expression (FAP-)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Fibrosarcoma	HT-1080 cells (FAP expression)		CVCL_0317
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	964 nM	Positive FAP expression (FAP+++/++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Fibrosarcoma	HT-1080 cells (FAP expression)		CVCL_0317

Experiment 1 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million breast cancer cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.1 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	Triple negative breast cancer PDX model (PDX: HBCx9)
Experiment 2 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 32.11%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million breast cancer cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.3 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	Triple negative breast cancer PDX model (PDX: HBCx9)
Experiment 3 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 73.25%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million breast cancer cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.6 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	Triple negative breast cancer PDX model (PDX: HBCx9)
Experiment 4 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79.64%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million breast cancer cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.2 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	Triple negative breast cancer PDX model (PDX: HCI-009)
Experiment 5 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.52%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million breast cancer cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.1 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	Triple negative breast cancer PDX model (PDX: HCI-009)
Experiment 6 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.52%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million breast cancer cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.5 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	Triple negative breast cancer PDX model (PDX: HCI-009)

Experiment 1 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million NCI-H1781 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.2 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	NCI-H1781 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 2 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 39.52%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million PC-9 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.2 mg/kg) through tail vein.
In Vivo Model	PC-9 CDX model
In Vitro Model	Lung adenocarcinoma	PC-9 cells		CVCL_B260
Experiment 3 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.74%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million NCI-H1781 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.5 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	NCI-H1781 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 4 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.26%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.2 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 5 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 67.78%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million PC-9 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.5 mg/kg) through tail vein.
In Vivo Model	PC-9 CDX model
In Vitro Model	Lung adenocarcinoma	PC-9 cells		CVCL_B260
Experiment 6 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.88%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million PC-9 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (1 mg/kg) through tail vein.
In Vivo Model	PC-9 CDX model
In Vitro Model	Lung adenocarcinoma	PC-9 cells		CVCL_B260
Experiment 7 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 73.90%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million PC-9 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (2 mg/kg) through tail vein.
In Vivo Model	PC-9 CDX model
In Vitro Model	Lung adenocarcinoma	PC-9 cells		CVCL_B260
Experiment 8 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.20%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.5 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 9 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.27%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million NCI-H1781 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (2 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	NCI-H1781 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 10 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.78%	Low LY6E expression (LY6E+)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million NCI-H1781 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (1 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	NCI-H1781 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 11 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.33%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (1 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 13.40%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	Non small cell lung cancer PDX model (PDX: 37622A1)

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 2.40%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 11.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 17.30%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 22.50%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 7 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29.80%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 8 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 33.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 9 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 33.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 10 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 33.70%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 11 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 34.70%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 12 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.90%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 13 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung squamous cell carcinoma	SW900 cells		CVCL_1731
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 15.50%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	Non small cell lung cancer PDX model (PDX: 37622A1)

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 1.40%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 1.80%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 12.90%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 15.80%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 7 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 38.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 8 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.50%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20%	Positive FAP expression (FAP+++/++)
Method Description	Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
In Vivo Model	Pancreatic adenocarcinoma PDX model (PDX: PAXF-736)

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.96 nM	Negative FAP expression (FAP-)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Fibrosarcoma	HT-1080 cells (FAP expression)		CVCL_0317
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	555 nM	Positive FAP expression (FAP+++/++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Fibrosarcoma	HT-1080 cells (FAP expression)		CVCL_0317

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≉ 33.30%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)
Experiment 2 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≋ 87%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, qw*3.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST430)

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≜ 33.80%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v. at day29, day 50.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST074)

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≛ 18.50%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg, i.v.*1.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≔ 38%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 0.3mpk.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)
Experiment 2 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≙ 50%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg, i.v. at day38, day 59.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST1)
Experiment 3 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≘ 56.30%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v. at day55, day 75.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST020)
Experiment 4 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≕ 83%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 1mpk.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)
Experiment 5 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≖ 90.40%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3mpk.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)
Experiment 6 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≚ 92%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v. at day38, day 59.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST1)

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 47.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	Non small cell lung cancer PDX model (PDX: 37622A1)

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 16.60%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 24.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 33.10%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.70%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.50%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 64.90%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 7 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 82%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 8 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 9 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.30%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	26 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	214 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	254 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.34 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.72 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.8 uM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.50%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	Non small cell lung cancer PDX model (PDX: 37622A1)

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 3.80%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 25.60%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 44.30%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 62.30%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 91.60%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 7 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.80%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 8 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.10%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 9 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	37 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	515 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	523 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	611 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.43 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.8 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 7 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.02 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≗ 60%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v. at day55, day 75.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST020)

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 65.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	Non small cell lung cancer PDX model (PDX: 37622A1)

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 23.90%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29.60%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29.60%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 38%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 46.90%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.70%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 7 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 86.80%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 8 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.80%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 9 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.3 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	148 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.15 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.24 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.24 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≓ 66.70%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 1 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 70%	Positive FAP expression (FAP+++/++)
Method Description	Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
In Vivo Model	Pancreatic adenocarcinoma PDX model (PDX: PAXF-736)

Experiment 1 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	90 nM	Positive FAP expression (FAP+++/++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Fibrosarcoma	HT-1080 cells (FAP expression)		CVCL_0317
Experiment 2 Reporting the Activity Date of This ADC					[14]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	108 nM	Negative FAP expression (FAP-)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Fibrosarcoma	HT-1080 cells (FAP expression)		CVCL_0317

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75.71%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of esophageal squamous cell carcinoma cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Esophageal squamous cell carcinoma PDX model (PDX: ES0204)
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.88%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of prostate cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Prostate cancer PDX model (PDX: PR9586)
Experiment 3 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.20%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of prostate cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Prostate cancer PDX model (PDX: PR9586)
Experiment 4 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.11%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of prostate cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Prostate cancer PDX model (PDX: PR9586)
Experiment 5 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of esophageal squamous cell carcinoma cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Esophageal squamous cell carcinoma PDX model (PDX: ES0204)
Experiment 6 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of esophageal squamous cell carcinoma cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Esophageal squamous cell carcinoma PDX model (PDX: ES0204)

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 78.90%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84.20%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.62 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	PC-9 cells		CVCL_B260
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.86 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082
Experiment 3 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.85 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-520 cells		CVCL_1355
Experiment 4 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.62 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 5 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.43 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 6 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	15.8 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 7 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	21.13 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 8 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	23.56 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≒ 76%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 1 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≑ 79%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 1 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.28%
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of esophageal squamous cell carcinoma cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Esophageal squamous cell carcinoma PDX model (PDX: ES0204)
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.81%
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of prostate cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Prostate cancer PDX model (PDX: PR9586)

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.64%
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 49.17%
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.80%
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≝ 81.30%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST430/654)
Experiment 2 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≎ 88.60%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 1 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 85.70%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 1 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)
Experiment 2 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≌ 92.80%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 86.60%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	Non small cell lung cancer PDX model (PDX: 37622A1)

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 18.30%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 19.40%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 28%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 33.30%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 46.90%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 57.50%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 7 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 66.40%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 8 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HCC2429 CDX model
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 9 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.70%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 10 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.80%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 11 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.50%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 12 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.10%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 13 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.20%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 14 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.2 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	306 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	473 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.18 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 7 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.27 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 8 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.27 nM	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≊ 87%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, qw*3.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST430)
Experiment 2 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.60%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≏ 90.50%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 1 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)

Experiment 1 Reporting the Activity Date of This ADC					[17]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 92.80%	Positive GPR20 expression (GPR20+++/++)
Method Description	To establish gastrointestinal stromal tumor model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 10 mg/kg, i.v.*1.
In Vivo Model	Gastrointestinal stromal tumor (GIST) PDX model (PDX: GIST-T1/GPR20)

Experiment 1 Reporting the Activity Date of This ADC					[19]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98%	High GPC1 expression(GPC1+++)
Method Description	Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model	Hepatocellular carcinoma PDX model (PDX: LI1097)
Experiment 2 Reporting the Activity Date of This ADC					[19]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High GPC1 expression(GPC1+++)
Method Description	Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model	Hepatocellular carcinoma PDX model (PDX: LI1037)
Experiment 3 Reporting the Activity Date of This ADC					[19]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High GPC1 expression(GPC1+++)
Method Description	Mice were treated with isotype control CD 70 antibody drug conjugate (ADC) or antiglypican 3 ADC at 0.75 mg/kg on Q7D4 schedule or at 5 mg/kg on QD1 schedule.
In Vivo Model	Hepatocellular carcinoma PDX model (PDX: LI1068)

Experiment 1 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established PDX model of bladder cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	Bladder cancer PDX model (PDX: BL9200)

Experiment 1 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.33%	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H322M CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H322M cells		CVCL_1557
Experiment 2 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H322M CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H322M cells		CVCL_1557

Experiment 1 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.1 ug/mL	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.57 ug/mL	High NECTIN4 expression (NECTIN4 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Bladder carcinoma	T24 cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish lung adenocarcinoma model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 11.25 mg/kg, i.v.
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84.50%	Positive EGFR expression (EGFR+++/++)
Method Description	To establish lung adenocarcinoma model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3.75 mg/kg, i.v.
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 3 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish gastric tubular adenocarcinoma model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3.75 mg/kg, i.v.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.70%	Positive EGFR expression (EGFR+++/++)
Method Description	To establish lung adenocarcinoma model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 11.25 mg/kg, i.v.
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	435.86 nM	Positive HER2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the NCI-N87 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58.56%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.16%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 4 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.19%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 5 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.65%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 6 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.58%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1 ug/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (8.3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (16.2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 49.65%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 49.90%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.48%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.81%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 6 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 82.90%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (ADC-211, 1 mg/kg plus ADC-106, 5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 7 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84.39%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (ADC-211, 1 mg/kg plus ADC-106, 1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58.22%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 5 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 73.26%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.50%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 3 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 70.20%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 4 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.26%	Low CD276 expression (CD276 +)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 5 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.60%	Low CD276 expression (CD276 +)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 6 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.20%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 7 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.40%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	49.26 nM	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	PC-9 cells		CVCL_B260
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	183.3 nM	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	Colo205 CDX model
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 2 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 16%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 23%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53%	High TROP2 expression (TROP2 +++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 5 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 73%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	Colo205 CDX model
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.27 nM	High TROP2 expression (TROP2 +++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 2 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.53 nM	High TROP2 expression (TROP2 +++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 3 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	50 nM	Positive TROP2 expression (TROP2 +++/++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	59.8 nM	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218
Experiment 5 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	75.58 nM	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung small cell carcinoma	DMS 53 cells		CVCL_1177
Experiment 6 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative TROP2 expression (TROP2 -)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0.31%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.23%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 1.62%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 0.5 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 43.50%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 1.56 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.91%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 3 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.62 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.75 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	506.44 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 4%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish lung adenocarcinoma model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 11.25 mg/kg, i.v.
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.20%	Positive EGFR expression (EGFR+++/++)
Method Description	To establish lung adenocarcinoma model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3.75 mg/kg, i.v.
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 3 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish gastric tubular adenocarcinoma model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3.75 mg/kg, i.v.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92%	Positive EGFR expression (EGFR+++/++)
Method Description	To establish lung adenocarcinoma model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 11.25 mg/kg, i.v.
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Positive HER2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the NCI-N87 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 6%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (12 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 8%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	THP-1 CDX model
In Vitro Model	Childhood acute monocytic leukemia	THP-1 cells		CVCL_0006
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MOLM 13 CDX model
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	103 pM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Childhood acute monocytic leukemia	THP-1 cells		CVCL_0006
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 3 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	173 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Promyelocytic leukemia	NB-4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 8.52%	Positive CD33 expression (CD33+++/++)
Method Description	Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.8 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	218 ng/mL	Positive CD33 expression (CD33+++/++)
Method Description	The cells, at a predeterminedconcentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5CO2, serialdilutions of each test article (TA) were added to the cells. Cells were incubated with test articlesfor 72 hours, and viability was detected with CellTiter-Glo reagent.
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 8.74%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 0.5 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.85%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 1.56 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.84%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 3 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.73 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.83 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 10.70%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted by, i.v, 1 mg/kg (day1 and day15) injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OCI-LY3 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	OCI-Ly3 cells		CVCL_8800
Experiment 2 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 20.60%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted by, i.v, 5 mg/kg (day1 and day15) injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Toledo CDX model
In Vitro Model	Diffuse large B-cell lymphoma	Toledo cells		CVCL_3611
Experiment 3 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≉ 33%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 2 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	KE97 CDX model
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 4 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 52.70%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted by, i.v, 2 mg/kg (day1 and day15) injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Toledo CDX model
In Vitro Model	Diffuse large B-cell lymphoma	Toledo cells		CVCL_3611
Experiment 5 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≊ 54%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	KE97 CDX model
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 6 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 74.60%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted by, i.v, 0.5 mg/kg (day1 and day15) injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OCI-LY3 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	OCI-Ly3 cells		CVCL_8800
Experiment 7 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 78.62%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	KE97 CDX model
In Vitro Model	Normal	KE-97 cells		CVCL_3386

Experiment 1 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.69 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Hodgkin lymphoma	SUP-HD1 cells		CVCL_2208
Experiment 2 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.17 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 3 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.24 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 4 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.28 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 5 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.29 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 6 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.94 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Hodgkin lymphoma	L-540 cells		CVCL_1362
Experiment 7 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.24 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	T-cell large granular lymphocyte leukemia	MOTN-1 cells		CVCL_2127
Experiment 8 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.62 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Mantle cell lymphoma	JVM-2 cells		CVCL_1319
Experiment 9 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.9 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Hodgkin lymphoma	L-540 cells		CVCL_1362
Experiment 10 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.61 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 11 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.42 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Diffuse large B-cell lymphoma	OCI-Ly3 cells		CVCL_8800
Experiment 12 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 20 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	T acute lymphoblastic leukemia	Peer cells		CVCL_1913
Experiment 13 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 20 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Chronic lymphocytic leukemia	MEC-2 cells		CVCL_1871

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 11.68%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 0.5 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 39.11%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 1.56 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.82%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 3 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.56 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.92 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.18 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 12.50%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	PA-1 CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 2 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 25%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	A375.S2 CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 3 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 32.60%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	NCI-H1703 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 4 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 42.30%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Calu-6 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 5 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 42.80%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	PA-1 CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 6 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.50%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Calu-6 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 7 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 65.20%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	NCI-H1703 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 8 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 65.40%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Calu-6 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 9 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	A375.S2 CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 10 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	A375.S2 CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 11 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.70%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	PA-1 CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 12 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.90%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 13 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.80%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	NCI-H1703 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490

Experiment 1 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	162 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	171 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 3 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	219 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 4 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	303 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Neoplasm	Hs 700T cells		CVCL_0858
Experiment 5 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	735 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 6 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	887 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A375 cells		CVCL_0132
Experiment 7 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	DU145 cells		CVCL_0105
Experiment 8 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 9 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 12.50%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	PA-1 CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 2 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 32.60%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	NCI-H1703 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 3 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 35.70%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	PA-1 CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 4 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.50%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	A375.S2 CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 5 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.50%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Calu-6 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 6 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 69.20%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Calu-6 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 7 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75.30%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	NCI-H1703 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 8 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 78.70%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	NCI-H1703 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 9 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	A375.S2 CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 10 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84.60%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Calu-6 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 11 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	A375.S2 CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 12 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 13 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	PA-1 CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479

Experiment 1 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	31 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	59 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 3 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	90 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 4 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	153 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A375 cells		CVCL_0132
Experiment 5 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	159 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Neoplasm	Hs 700T cells		CVCL_0858
Experiment 6 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	221 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 7 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	352 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 8 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	555 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 9 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	DU145 cells		CVCL_0105

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 12.68%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.3 ng/mL	High HER2 expression (HER2 +++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	103 ng/mL	High HER2 expression (HER2+++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≌ 13.77%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 2 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	KE97 CDX model
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 2 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 33%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	KE97 CDX model
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 3 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≋ 85.38%	Positive CCR7 expression (CCR7+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	KE97 CDX model
In Vitro Model	Normal	KE-97 cells		CVCL_3386

Experiment 1 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.98 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.18 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 3 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.91 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Hodgkin lymphoma	L-540 cells		CVCL_1362
Experiment 4 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.42 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 14.30%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 14.30%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HEY C2 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	HEY C2 cells		CVCL_X009
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 42%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	A-375 CDX model
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58.30%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	HEY C2 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	HEY C2 cells		CVCL_X009

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 15.01%	Positive HER2 expression (HER2 +++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.p.ONCE of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-BR-3 CDX model
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 46.22%	Positive HER2 expression (HER2 +++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p.*2 of one of the conjugates listed above or with PBS only.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.77%	Positive HER2 expression (HER2 +++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.p.*2 of one of the conjugates listed above or with PBS only.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 77.40%	Positive HER2 expression (HER2 +++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 6 mg/kg, i.p.ONCE of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-BR-3 CDX model
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 15.40%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Calu-6 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 2 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 18.80%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	PA-1 CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 3 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 21.40%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	PA-1 CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 4 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 32.60%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	NCI-H1703 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 5 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.50%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	A375.S2 CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 6 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.50%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Calu-6 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 7 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 65%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	PA-1 CDX model
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 8 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 70%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	A375.S2 CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 9 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.80%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MDA-MB-468 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 10 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.40%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	NCI-H1703 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 11 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	A375.S2 CDX model
In Vitro Model	Amelanotic melanoma	A375.S2 cells		CVCL_0136
Experiment 12 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Calu-6 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 13 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive CD276 expression (CD276+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	NCI-H1703 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490

Experiment 1 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	16 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	30 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 3 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	43 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 4 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	109 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Neoplasm	Hs 700T cells		CVCL_0858
Experiment 5 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	124 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 6 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	201 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 7 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	267 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A375 cells		CVCL_0132
Experiment 8 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	409 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian mixed germ cell tumor	PA-1 cells		CVCL_0479
Experiment 9 Reporting the Activity Date of This ADC					[30]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	465 pM	Positive CD276 expression (CD276+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	DU145 cells		CVCL_0105

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 15.63%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.61%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.4 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.58%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 35.37%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 0.5 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.28%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 1 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 ng/mL	High HER2 expression (HER2 +++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.3 ng/mL	High HER2 expression (HER2+++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 16.12%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 40.75%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.27%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (4 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.28%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.34%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 6 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.59%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (8 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 34.22%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 15 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 16.30%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 17.49%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 0.5 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.28%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 1.56 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.20%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 3 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.77 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.85 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.93 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 19.40%	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 19.51%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 19.82%	Positive HER2 expression (HER2 +++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.p.ONCE of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-BR-3 CDX model
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.38%	Positive HER2 expression (HER2 +++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 6 mg/kg, i.p.ONCE of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-BR-3 CDX model
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 20.29%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 0.5 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 55.70%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 1.56 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.48%	High HER2 expression (HER2+++)
Method Description	For efficacy study, 7.5 million tumor cells in 50% matrigel are implanted subcutaneously into 6-8 weeks old nude mice until the tumor sizes reach between 250 and 350 mm3. Dosing is done through bolus tail vein injection. Depending on the tumor response totreatment, animals are injected with 3 mg/kg of antibody drug conjugates treated four times everyfour days.    Click to Show/Hide
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.76 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.99 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.22 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 23.73%	Positive CD33 expression (CD33+++/++)
Method Description	Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.6 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24.2 ng/mL	Positive CD33 expression (CD33+++/++)
Method Description	The cells, at a predeterminedconcentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5CO2, serialdilutions of each test article (TA) were added to the cells. Cells were incubated with test articlesfor 72 hours, and viability was detected with CellTiter-Glo reagent.
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 24.11%	Low CD276 expression (CD276 +)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	76.37 ug/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 24.12%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.80%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 66.89%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (12 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79.46%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (18 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 24.14%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 24.69%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (8 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 54.57%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.33%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.40%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 66.98%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (16.4 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 6 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 74.48%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79.58%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 5 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.52%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.58%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 15 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 24.87%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.61%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.98%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 69.44%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.56%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 6 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.69%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.4 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.34%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 1 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 26.29%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 36.16%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 47.36%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 4 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.36%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 5 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.03%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 6 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.38%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 26.83%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.69%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.70%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.69%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.69%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 28.32%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 48.87%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 28.50%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29.92%	Low CD276 expression (CD276 +)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75.74%	Low CD276 expression (CD276 +)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 30.37%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 31.10%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 31.90%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 66.50%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.33 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.35 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 32%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 2 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High TROP2 expression (TROP2 +++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.14 nM	High TROP2 expression (TROP2 +++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 2 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.23 nM	High TROP2 expression (TROP2 +++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 3 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	39.23 nM	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218
Experiment 4 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	42.46 nM	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung small cell carcinoma	DMS 53 cells		CVCL_1177
Experiment 5 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	50 nM	Positive TROP2 expression (TROP2 +++/++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 6 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative TROP2 expression (TROP2 -)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 32.80%	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 33.92%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.81%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.38%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.68 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	34.39 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	42.92 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2650.34 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5156.08 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 6 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6434.14 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	35%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.86 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 36.64%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 37.30%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.38 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	PC-9 cells		CVCL_B260
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.48 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Skin squamous cell carcinoma	A431 cells		CVCL_0037
Experiment 3 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.84 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-520 cells		CVCL_1355
Experiment 4 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.16 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082
Experiment 5 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.44 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 6 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	8.06 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 37.80%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 38.29%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 38.56%	Positive CD33 expression (CD33+++/++)
Method Description	Mice were orthotopically implanted with 1x107 MV411 cells suspended in amixture of Matrigel and culture media in the inguinal fat pad. Following group allocation, mice were treated with a single 10 ml/kg lateral tail vein injection of a CD33-D antibody-Compound (XL) conjugate at 10 mg/kg QWx2.
In Vivo Model	MV411 CDX model
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.27 nM	Positive CD33 expression (CD33+++/++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 39.10%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.9 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.9 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 39.22%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.24%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 40.60%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of U87MG cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.30%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of U87MG cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 40.85%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of Detroit562 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Detroit 562 CDX model
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 62.55%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of Detroit562 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Detroit 562 CDX model
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23.72 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	26.54 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	26.9 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	29 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 5 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	196.6 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Renal carcinoma	A498 cells		CVCL_1056
Experiment 6 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Negative CD276 expression (CD276 -)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 41.40%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.4 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.5 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 42.53%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (1.5 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.72%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	43%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.4 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 43.13%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 66.14%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.73%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.54%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.06%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 23.58%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 2 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.56 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.7 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.7 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	44.5 ng/mL	High HER2 expression (HER2 +++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	57.4 ng/mL	High HER2 expression (HER2+++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 6 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	234.11 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 7 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	254.2 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 8 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1303.63 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 44%	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 55.20%	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 78.40%	Positive MUC16 expression (MUC16+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 44%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.64%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	SW480 CDX model
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 44.26%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of Detroit562 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Detroit 562 CDX model
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.27%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of Detroit562 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Detroit 562 CDX model
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	31.6 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	33.3 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	49.1 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	70.6 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 5 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	418.9 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Renal carcinoma	A498 cells		CVCL_1056
Experiment 6 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Negative CD276 expression (CD276 -)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 44.70%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.05 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 63.20%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 65.80%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.88 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 45%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 47.50%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.05 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 87.50%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.17 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.20%	Positive HER2 expression (HER2 +++/++)
Method Description	Mice were orthotopically implanted with 1x107 HCC1569 human breast cancer cells suspended in amixture of Matrigel and culture media in the inguinal fat pad. Following group allocation, mice were treated with a single 10 ml/kg lateral tail vein injection of a Pertuzumab-Compound (XI) conjugate at 3 mg/kg.
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.40%	Positive HER2 expression (HER2 +++/++)
Method Description	Mice were orthotopically implanted with 1x107 HCC1569 human breast cancer cells suspended in amixture of Matrigel and culture media in the inguinal fat pad. Following group allocation, mice were treated with a single 10 ml/kg lateral tail vein injection of a Pertuzumab-Compound (XI) conjugate at 10 mg/kg.
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.70%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	46%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1 was selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H1650). The dose was 1 mg/kg/IP/QDx1.
In Vivo Model	H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	48%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1 was selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H1650). The dose was 3 mg/kg/IP/QDx1.
In Vivo Model	H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 3 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	56%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 4 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	60%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 5 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	62%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1 was selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H1650). The dose was 10 mg/kg/IP/QDx1.
In Vivo Model	H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 6 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	67%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 7 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	88%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 8 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	98%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 9 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H146 small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	47%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	50%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 3 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	60%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 4 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	63%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 5 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 6 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 7 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.24 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 47.50%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.05 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 67.50%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 75%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	11.3 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 47.70%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of U87MG cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.80%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of U87MG cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3mpk, QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 49.10%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.025 mg/kg ADC.    Click to Show/Hide
In Vivo Model	Raji CDX model
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.10%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.025 mg/kg ADC.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.70%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.05 mg/kg ADC.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 4 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.037mg/kg ADC.    Click to Show/Hide
In Vivo Model	NHT-34 CDX model
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071
Experiment 5 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.10%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.111 mg/kg ADC.    Click to Show/Hide
In Vivo Model	NHT-34 CDX model
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071
Experiment 6 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.40%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.1 mg/kg ADC.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 7 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.1 mg/kg ADC.    Click to Show/Hide
In Vivo Model	Raji CDX model
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 8 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.05 mg/kg ADC.    Click to Show/Hide
In Vivo Model	Raji CDX model
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 9 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 0.333 mg/kg ADC.    Click to Show/Hide
In Vivo Model	NHT-34 CDX model
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071

Experiment 1 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.5 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071
Experiment 2 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.8 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 3 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.9 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Burkitt lymphoma	CA46 cells		CVCL_1101
Experiment 4 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	MM1.S cells		CVCL_8792
Experiment 5 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	MM1.R cells		CVCL_8794
Experiment 6 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells		CVCL_2481
Experiment 7 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	U-266 cells		CVCL_0015

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 50.92%	Positive ROR1 expression (ROR1 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.52%	Positive ROR1 expression (ROR1 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	36.16 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	39.69 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 3 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	42.58 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	112.6 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	51%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.18 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.05%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 68.38%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.44%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.08%	Positive ROR1 expression (ROR1 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 59.14%	Positive ROR1 expression (ROR1 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.6 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.35 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.69%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (1.5 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.84%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.90%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.1 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.4 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	52%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP).
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	58%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP).
In Vivo Model	EBC-1 CDX model
In Vitro Model	Lung squamous cell carcinoma	EBC-1 cells		CVCL_2891
Experiment 3 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	80%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP).
In Vivo Model	NCI-H1299 CDX model
In Vitro Model	Lung large cell carcinoma	NCI-H1299 cells		CVCL_0060
Experiment 4 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	88%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473
Experiment 5 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 6 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	97%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	NCI-H1299 CDX model
In Vitro Model	Lung large cell carcinoma	NCI-H1299 cells		CVCL_0060
Experiment 7 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	EBC-1 CDX model
In Vitro Model	Lung squamous cell carcinoma	EBC-1 cells		CVCL_2891

Experiment 1 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.38%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 57.69%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.71%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 4 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.76%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.40%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.90%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	A-375 CDX model
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.40%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	A-375 CDX model
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.80%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.5 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.9 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 52.89%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2.2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79.85%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 53.82%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3.3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 60.26%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 73.60%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (9 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 54%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	THP-1 CDX model
In Vitro Model	Childhood acute monocytic leukemia	THP-1 cells		CVCL_0006
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MOLM 13 CDX model
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	596 pM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Childhood acute monocytic leukemia	THP-1 cells		CVCL_0006
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 3 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	500 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Promyelocytic leukemia	NB-4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 54.06%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 54.09%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (1.5 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.71%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.72%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 54.40%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.3 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.1 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 56.20%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Detroit 562 CDX model
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 57.10%	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 85.70%	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 57.90%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 95%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 20 ug/m2 x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58.01%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.18%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.50%	High TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	Colo205 CDX model
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 5 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.70%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 6 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.84%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	Colo205 CDX model
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218
Experiment 7 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 8 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	77.6 nM	High TROP2 expression (TROP2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	393.9 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58.75%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (2 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	High HER2 expression (HER2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	High HER2 expression (HER2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73.11 nM	Low HER2 expression (HER2-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73.11 nM	Low HER2 expression (HER2-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 59.94%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (0.5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84.27%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.06%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.73%	Positive CD22 expression (CD22+++/++)
Method Description	Inoculate 150 mice with WSU-DLCL2 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (2 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 CDX model
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.35%	Positive HER2 expression (HER2+++/++)
Method Description	Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (5 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	KPL-4 CDX model
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 40.52%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 0.5 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 69.41%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 2 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.57%	Positive HER2 expression (HER2+++/++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 5 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.46 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.96 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.27 nM	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902
Experiment 4 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.6 ng/mL	High HER2 expression (HER2 +++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 5 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1 ng/mL	High HER2 expression (HER2+++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 6 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1268.7 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 7 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1342.6 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 8 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1689.31 ng/mL	Positive CD22 expression (CD22+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Diffuse large B-cell lymphoma	WSU-DLCL2 cells		CVCL_1902

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 61.80%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.2 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.2 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 62.50%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.05 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 62.50%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 80%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.75 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 62.77%	Positive HER2 expression (HER2 +++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p.*2 of one of the conjugates listed above or with PBS only.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.32%	Positive HER2 expression (HER2 +++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.p.*2 of one of the conjugates listed above or with PBS only.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MOLM 13 CDX model
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MV4-11 CDX model
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	16.7 pM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.30%	Positive CD33 expression (CD33+++/++)
Method Description	Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.4 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79.11%	Positive CD33 expression (CD33+++/++)
Method Description	Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.7 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.9 ng/mL	Positive CD33 expression (CD33+++/++)
Method Description	The cells, at a predeterminedconcentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5CO2, serialdilutions of each test article (TA) were added to the cells. Cells were incubated with test articlesfor 72 hours, and viability was detected with CellTiter-Glo reagent.
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.30%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	U87MG CDX model
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.33%	Positive HER2 expression (HER2+++/++)
Method Description	Nude mice were implanted with SK-OV-3 tumor cells which were allowed to establish tumors of ~150 mm3 prior to initiation of treatment. ADCs at 10 mg/kg doses were injected through tail vein on days 38, 45, 52 and 59. There were ~10 mice per group. The tumor volume of mice in different group was measured and their survival was recorded.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.97 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 64.50%	Positive FOLR1 expression (FOLR1+++/++)
Method Description	To establish ovarian cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 5 mg/kg.
In Vivo Model	OV-90 CDX model
In Vitro Model	Ovarian adenocarcinoma	OV-90 cells		CVCL_3768
Experiment 2 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.20%	Positive FOLR1 expression (FOLR1+++/++)
Method Description	To establish lung cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 5 mg/kg.
In Vivo Model	NCI-H292 CDX model
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive FOLR1 expression (FOLR1+++/++)
Method Description	To establish oral epidermal cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 5 mg/kg.
In Vivo Model	KB CDX model
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

Experiment 1 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	29.1 nM	Positive FOLR1 expression (FOLR1+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the JEG-3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Gestational choriocarcinoma	JEG-3 cells		CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	62.4 nM	Positive FOLR1 expression (FOLR1+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the OVCAR3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[42]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	173.5 nM	Positive FOLR1 expression (FOLR1+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the KB cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Human papillomavirus-related endocervical adenocarcinoma	KB cells		CVCL_0372

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 64.52%	Positive CD33 expression (CD33+++/++)
Method Description	Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.4 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.28%	Positive CD33 expression (CD33+++/++)
Method Description	Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.9 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	337 ng/mL	Positive CD33 expression (CD33+++/++)
Method Description	The cells, at a predeterminedconcentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5CO2, serialdilutions of each test article (TA) were added to the cells. Cells were incubated with test articlesfor 72 hours, and viability was detected with CellTiter-Glo reagent.
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 65%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MV4-11 CDX model
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 68%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MOLM 13 CDX model
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	686 pM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064
Experiment 3 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	71.9 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Promyelocytic leukemia	NB-4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	65%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.85 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 65.40%	Low HER2 expression (HER2-)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 68.86%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (2 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96%	Low HER2 expression (HER2-)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (2 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	High HER2 expression (HER2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	High HER2 expression (HER2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.1 nM	Low HER2 expression (HER2-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	39.91 nM	Low HER2 expression (HER2-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 67%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MOLM 13 CDX model
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 68%	Positive CD123 expression (CD123+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	MV4-11 CDX model
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	137 pM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	933 pM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 67.40%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.60%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	A-375 CDX model
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.70%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.5 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.8 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 67.80%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 68.25%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.60%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	33.14 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	33.49 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 70%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.05 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 77.50%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 80%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.73 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 70.60%	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.27%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	Detroit 562 CDX model
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 72.50%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 73.17%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 74.20%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 93.50%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	Colo205 CDX model
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	76%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.37 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.24%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.3 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.29%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (6 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 3 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.29%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (3 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 4 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.29%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (1 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 5 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.34%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (10 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 76.69%	Positive CD33 expression (CD33+++/++)
Method Description	Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.2 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.34%	Positive CD33 expression (CD33+++/++)
Method Description	Single intravenous (IV) administration of ADCs to mice bearing HL-60 AML xenografts, each conjugate (in 0.7 mg/kg) that were administered once IV at the day 0 time point.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 ng/mL	Positive CD33 expression (CD33+++/++)
Method Description	The cells, at a predeterminedconcentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5CO2, serialdilutions of each test article (TA) were added to the cells. Cells were incubated with test articlesfor 72 hours, and viability was detected with CellTiter-Glo reagent.
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 77.51%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3.72 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.12%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	79%	Positive CD276 expression (CD276 +++/++)
Method Description	In vivo xenograft model of small cell lung cancer (using NCI-H146 cells). Single dose treatment of the tumor bearing mice resulted in tumor growthinhibition and tumor growth delay. Mice were administered 6 mg/kg of the ADC intraperitoneally IP/QDx1.
In Vivo Model	NCI-H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.39 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.39 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79.46%	Positive HER2 expression (HER2+++/++)
Method Description	Nude mice were implanted with SK-OV-3 tumor cells which were allowed to establish tumors of ~150 mm3 prior to initiation of treatment. ADCs at 10 mg/kg doses were injected through tail vein on days 38, 45, 52 and 59. There were ~10 mice per group. The tumor volume of mice in different group was measured and their survival was recorded.
In Vivo Model	SK-OV-3 CDX model
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.45 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[41]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	80%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (QDx1/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (QDx1/IP) plus Docetaxel 7.5 mg/kg (QDx1/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.18 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.28%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	HT-29 CDX model
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	31.67 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	34.15 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.39%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (2 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	81%	Positive CD276 expression (CD276 +++/++)
Method Description	Anti-tumor activity in a mouse small celllung cancer cell line xenograft model NCI-H146, of human origin. Mice were administered 10 mg/kg of the ADC intraperitoneally IP/QDx1.
In Vivo Model	NCI-H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	81%	Positive CD276 expression (CD276 +++/++)
Method Description	In vivo xenograft model of small cell lung cancer (using NCI-H146 cells). Single dose treatment of the tumor bearing mice resulted in tumor growthinhibition and tumor growth delay. Mice were administered 6 mg/kg of the ADC intraperitoneally IP/QDx1.
In Vivo Model	NCI-H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.3 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.32 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.41%	Moderate HER2 expression (HER2++)
Method Description	Six-week old intact female NMRI nu/nu athymic mice were purchaseo and randomly divided into three groups of eight mice each. 5,000,000 JIMT-cells were injected s.c. into the flank of each mouse. The Her-30.1036 [4.0] was injected once i.v. at a doseof 30 ug/kg with respect to amanitin at day 14.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.97%	Moderate HER2 expression (HER2++)
Method Description	Six-week old intact female NMRI nu/nu athymic mice were purchaseo and randomly divided into three groups of eight mice each. 5,000,000 JIMT-cells were injected s.c. into the flank of each mouse. The Her-30.1036 [4.0] was injected once i.v. at a doseof 150 ug/kg with respect to amanitin at day 14.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate HER2 expression (HER2++)
Method Description	Six-week old intact female NMRI nu/nu athymic mice were purchaseo and randomly divided into three groups of eight mice each. 5,000,000 JIMT-cells were injected s.c. into the flank of each mouse. The Her-30.1036 [4.0] was injected once i.v. at a doseof 150 ug/kg with respect to amanitin at day 14.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate HER2 expression (HER2++)
Method Description	Six-week old intact female NMRI nu/nu athymic mice were purchaseo and randomly divided into three groups of eight mice each. 5,000,000 JIMT-cells were injected s.c. into the flank of each mouse. The Her-30.1036 [4.0] was injected once i.v. at a doseof 30 ug/kg with respect to amanitin at day 14.
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	High HER2 expression (HER2 +++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO2 by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	High HER2 expression (HER2 +++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO2 by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.1 nM	Moderate HER2 expression (HER2++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO2 by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.83%	Moderate HER2 expression (HER2++)
Method Description	Six days after JIMT-3 cell implantation, when tumors reached an average size of 220-230 mm3, the animals were divided into groups of 6 mice according to tumor sizeand aspect. All compounds were injected intraperitoneally (i.p.). In this example, the anti-tumor activity of Tratuzumab mAb coupled with E-13 at about DAR 4 was evaluated after 1 injections of a 3 mg/kg dose at D6.    Click to Show/Hide
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Six days after Calu-3 cell implantation, when tumors reached an average size of 250-260 mm3, the animals were divided into groups of 6 mice according to tumor sizeand aspect. All compounds were injected intraperitoneally (i.p.). In this example, the anti-tumor activity of Tratuzumab mAb coupled with E-13 at about DAR 4 was evaluated after 1 injections of a 3 mg/kg dose at D6.    Click to Show/Hide
In Vivo Model	Calu-3 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 81.97%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (1 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 82%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	120.8 nM	High TROP2 expression (TROP2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	447.5 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 82.41%	Moderate HER2 expression (HER2++)
Method Description	Six days after JIMT-3 cell implantation, when tumors reached an average size of 220-230 mm3, the animals were divided into groups of 6 mice according to tumor sizeand aspect. All compounds were injected intraperitoneally (i.p.). In this example, the anti-tumor activity of Tratuzumab mAb coupled with G-13 at about DAR 4 was evaluated after 1 injections of a 3 mg/kg dose at D6.    Click to Show/Hide
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Six days after Calu-3 cell implantation, when tumors reached an average size of 250-260 mm3, the animals were divided into groups of 6 mice according to tumor sizeand aspect. All compounds were injected intraperitoneally (i.p.). In this example, the anti-tumor activity of Tratuzumab mAb coupled with G-13 at about DAR 4 was evaluated after 1 injections of a 3 mg/kg dose at D6.    Click to Show/Hide
In Vivo Model	Calu-3 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.80%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	83%	Positive CD276 expression (CD276 +++/++)
Method Description	In vivo xenograft model of small cell lung cancer (using NCI-H146 cells). Single dose treatment of the tumor bearing mice resulted in tumor growthinhibition and tumor growth delay. Mice were administered 6 mg/kg of the ADC intraperitoneally IP/QDx1.
In Vivo Model	NCI-H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.9 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.9 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.10%	Positive SLITRK6 expression (SLITRK6+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Bladder cancer PDX model (PDX: SQ11-031)
Experiment 2 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.70%	Positive SLITRK6 expression (SLITRK6+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Bladder cancer PDX model (PDX: SQ09-083)
Experiment 3 Reporting the Activity Date of This ADC					[46]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.30%	Positive SLITRK6 expression (SLITRK6+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Bladder cancer PDX model (PDX: SQ09-041)

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.65%	Moderate CLDN18.2 expression (CLDN18.2 ++)
Method Description	Conjugates of the exemplary anti-CLDN18.2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3mpk of one of the conjugates listed above or with PBS only.
In Vivo Model	NUGC4 CDX model
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.04%	Moderate CLDN18.2 expression (CLDN18.2 ++)
Method Description	Conjugates of the exemplary anti-CLDN18.2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10mpk of one of the conjugates listed above or with PBS only.
In Vivo Model	NUGC4 CDX model
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.23 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84%	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model of NCI-H358 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H358 CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.75 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	22.48 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 84.45%	Moderate CLDN18.2 expression (CLDN18.2 ++)
Method Description	Conjugates of the exemplary anti-CLDN18.2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3mpk of one of the conjugates listed above or with PBS only.
In Vivo Model	NUGC4 CDX model
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 87.47%	Moderate CLDN18.2 expression (CLDN18.2 ++)
Method Description	Conjugates of the exemplary anti-CLDN18.2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10mpk of one of the conjugates listed above or with PBS only.
In Vivo Model	NUGC4 CDX model
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.33 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (2-B short reservation).
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.86 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (2-B short reservation).
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 3 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.31 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (2-B long reservation).
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 4 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.11 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (2-B long reservation).
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	85%	Positive CD276 expression (CD276 +++/++)
Method Description	In vivo xenograft model of small cell lung cancer (using NCI-H146 cells). Single dose treatment of the tumor bearing mice resulted in tumor growthinhibition and tumor growth delay. Mice were administered 6 mg/kg of the ADC intraperitoneally IP/QDx1.
In Vivo Model	NCI-H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.29 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.29 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	86%	Positive CD276 expression (CD276 +++/++)
Method Description	In vivo xenograft model of small cell lung cancer (using NCI-H146 cells). Single dose treatment of the tumor bearing mice resulted in tumor growthinhibition and tumor growth delay. Mice were administered 6 mg/kg of the ADC intraperitoneally IP/QDx1.
In Vivo Model	NCI-H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	86%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 86.13%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.46%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.69%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711
Experiment 4 Reporting the Activity Date of This ADC					[22]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.71%	Moderate CD22 expression (CD22++)
Method Description	Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	BJAB CDX model
In Vitro Model	Burkitt lymphoma	BJAB cells		CVCL_5711

Experiment 1 Reporting the Activity Date of This ADC					[48]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 86.70%	Moderate CD8 expression (CD8 ++)
Method Description	CT26 Cells were implanted subcutaneously (s.c.) in the right flank of the mice using 3x106 cells per animal. Mice received three injections of either 1 g F8-TNF (WEHI-164 tumor-bearing mice) or 2.5 g (CT26 tumor-bearing mice) every 48 h starting on the day after vaccination.
In Vivo Model	CT26 CDX model
In Vitro Model	Colon carcinoma	CT26 cells		CVCL_7254

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	87%	Positive CD276 expression (CD276 +++/++)
Method Description	Anti-tumor activity in a mouse small celllung cancer cell line xenograft model NCI-H146, of human origin. Mice were administered 10 mg/kg of the ADC intraperitoneally IP/QDx1.
In Vivo Model	NCI-H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	87%	Positive CD276 expression (CD276 +++/++)
Method Description	In vivo xenograft model of small cell lung cancer (using NCI-H146 cells). Single dose treatment of the tumor bearing mice resulted in tumor growthinhibition and tumor growth delay. Mice were administered 6 mg/kg of the ADC intraperitoneally IP/QDx1.
In Vivo Model	NCI-H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (3 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive TROP2 expression (TROP2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (10 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.84%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (1 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.10%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[43]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate MUC16 expression (MUC16++)
Method Description	Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 89.77%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.20%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 3 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (6 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	90%	Positive CD276 expression (CD276 +++/++)
Method Description	Anti-tumor activity in a mouse small celllung cancer cell line xenograft model NCI-H146, of human origin. Mice were administered 10 mg/kg of the ADC intraperitoneally IP/QDx1.
In Vivo Model	NCI-H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.28 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.61%	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H322M CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H322M cells		CVCL_1557
Experiment 2 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H322M CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H322M cells		CVCL_1557

Experiment 1 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	206.1 ng/mL	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.28 ug/mL	High NECTIN4 expression (NECTIN4 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Bladder carcinoma	T24 cells		CVCL_0554
Experiment 3 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.39 ug/mL	High NECTIN4 expression (NECTIN4 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023
Experiment 4 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.38 ug/mL	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.64%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.71%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.91%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.2 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.17%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (0.5 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 3 Reporting the Activity Date of This ADC					[15]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.02%	Moderate LY6E expression (LY6E++)
Method Description	Female C.B-17 SCD-beige mice were each inoculated in the thoracic mammary fat pad area with 5 million HCC1569 cells suspended in HBSS/matrigel. When the xenograft tumors reached an average tumor volume of 100-300 mm(referred to as Day 0), animals were received a single intravenous injection of the antibody-drug conjugate (1 mg/kg) through tail vein.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.47 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.57 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H847 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung small cell carcinoma	NCI-H847 cells		CVCL_1596
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.62 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.7 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H847 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung small cell carcinoma	NCI-H847 cells		CVCL_1596
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.03%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.05%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (2 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 93.79%	High HER2 expression (HER2+++/++)
Method Description	Inoculate mice with gastric cancer cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped. A single treatment will be administered intravenously (2 mg/kg, i.p.x1) via the tail vein on Day 0.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	High HER2 expression (HER2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	76.7 nM	Low HER2 expression (HER2-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Tumor Growth Inhibition value (TGI)	94%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.3 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H847 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung small cell carcinoma	NCI-H847 cells		CVCL_1596

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.58%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (1 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.30%	Positive HER2 expression (HER2 +++/++)
Method Description	Inoculate 150 mice with HCC1569 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.    Click to Show/Hide
In Vivo Model	HCC1569 CDX model
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.03%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 97.69%	Positive IGF1R expression (IGF1R+++/++)
Method Description	Twenty days after MCF-7 cell implantation, when tumors reached an average size of 120-150 mm3, the animals were divided into groups of 5 mice according to tumor size and aspect. All compounds were injected intraperitoncally (i.p.). In this example, the anti-tumor activity of ADCs at about DAR 4 was evaluated after 2 injections of a 7 mg/kg dose at day 20 and day 27.    Click to Show/Hide
In Vivo Model	MCF-7 CDX model
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.45%	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.80%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 5 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 2 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 11.33 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 3 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 20 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 4 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 30 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 5 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 20 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782
Experiment 6 Reporting the Activity Date of This ADC					[49]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive STEAP2 expression (STEAP2+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 10 mg/kg ADC.    Click to Show/Hide
In Vivo Model	C4-2 CDX model
In Vitro Model	Lymph node metastasis of prostate carcinoma	LNCaP C4-2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 100%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 100%	Positive CD33 expression (CD33+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	HL-60 CDX model
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≐ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 20 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≏ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≎ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1.25 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.77 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 20 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≌ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≋ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1.25 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	6.28 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≊ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 20 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≉ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (HER2+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 1.25 mg/kg, iv.*1 to thetail of each mouse.
In Vivo Model	BT-474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.47 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	A-375 CDX model
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive IL13 expression (IL13+++/++)
Method Description	Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model	PC3-MM2 CDX model
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.2 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.2 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459

Experiment 1 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 3 mg/kg ADC.    Click to Show/Hide
In Vivo Model	NHT-34 CDX model
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071
Experiment 2 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 1 mg/kg ADC.    Click to Show/Hide
In Vivo Model	NHT-34 CDX model
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071

Experiment 1 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071
Experiment 2 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 3 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Burkitt lymphoma	CA46 cells		CVCL_1101
Experiment 4 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	U-266 cells		CVCL_0015
Experiment 5 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	MM1.R cells		CVCL_8794
Experiment 6 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	MM1.S cells		CVCL_8792
Experiment 7 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	22 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	EJM cells		CVCL_2030
Experiment 8 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	455 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells		CVCL_2481

Experiment 1 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 3 mg/kg ADC.    Click to Show/Hide
In Vivo Model	NHT-34 CDX model
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071
Experiment 2 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	Tumours were induced subcutaneously by injecting NHT-34 cells in 100 uL of RPMI 1640 containing matrigel into the right flank of male Balb/c nude mice. Treatments were started when the tumors reached a mean volume of 200-300 mm3. Mice were randomized according to their individual tumor volume into groups and received a single i.v, 1 mg/kg ADC.    Click to Show/Hide
In Vivo Model	NHT-34 CDX model
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071

Experiment 1 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 2 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	19 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071
Experiment 3 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	22 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	U-266 cells		CVCL_0015
Experiment 4 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	44 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Burkitt lymphoma	CA46 cells		CVCL_1101
Experiment 5 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	162 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	EJM cells		CVCL_2030
Experiment 6 Reporting the Activity Date of This ADC					[38]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	696 ng/mL	Positive SLAMF6 expression (SLAMF6+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma	MM1.R cells		CVCL_8794

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High HER2 expression (HER2+++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with NCI-N87 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (1.5 mg/kg) on day 1.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.53 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive IGF1R expression (IGF1R+++/++)
Method Description	Twenty days after MCF-7 cell implantation, when tumors reached an average size of 120-150 mm3, the animals were divided into groups of 5 mice according to tumor size and aspect. All compounds were injected intraperitoncally (i.p.). In this example, the anti-tumor activity of ADCs at about DAR 4 was evaluated after 2 injections of a 7 mg/kg dose at day 20 and day 27.    Click to Show/Hide
In Vivo Model	MCF-7 CDX model
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive IGF1R expression (IGF1R+++/++)
Method Description	Twenty days after MCF-7 cell implantation, when tumors reached an average size of 120-150 mm3, the animals were divided into groups of 5 mice according to tumor size and aspect. All compounds were injected intraperitoncally (i.p.). In this example, the anti-tumor activity of ADCs at about DAR 4 was evaluated after 2 injections of a 7 mg/kg dose at day 20 and day 27.    Click to Show/Hide
In Vivo Model	MCF-7 CDX model
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive TROP2 expression (TROP2+++/++)
Method Description	To establish squamous carcinoma model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 5 mg/kg.
In Vivo Model	NCI-H2170 CDX model
In Vitro Model	Lung squamous cell carcinoma	NCI-H2170 cells		CVCL_1535

Experiment 1 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	41.56 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the NCI-H2170 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Lung squamous cell carcinoma	NCI-H2170 cells		CVCL_1535
Experiment 2 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	91.85 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[50]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	346.96 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the LK-2 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Lung squamous cell carcinoma	LK-2 cells		CVCL_1377

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[51]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive ROR1 expression (ROR1 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H1975 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive ROR1 expression (ROR1 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-N87 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	21 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	45.66 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 3 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	54.41 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73.19 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	NCI-H322M CDX model
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H322M cells		CVCL_1557

Experiment 1 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	229.2 ng/mL	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.05 ug/mL	High NECTIN4 expression (NECTIN4 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	Colo205 CDX model
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	Colo205 CDX model
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.18 nM	High TROP2 expression (TROP2 +++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 2 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.31 nM	High TROP2 expression (TROP2 +++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 3 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	50 nM	Positive TROP2 expression (TROP2 +++/++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	52.75 nM	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218
Experiment 5 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	72.92 nM	Moderate TROP2 expression (TROP2 ++)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung small cell carcinoma	DMS 53 cells		CVCL_1177
Experiment 6 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative TROP2 expression (TROP2 -)
Method Description	Conjugate in various concentrations was added to TROP2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

Experiment 1 Reporting the Activity Date of This ADC					[24]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%	High TROP2 expression (TROP2 +++)
Method Description	Conjugates of the exemplary anti-TROP2 antibodies were tested using an established xenograft model of NUGC4 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model	FaDu CDX model
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 56.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 0%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 12.95%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 6 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 15.20%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 16.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 94.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 16.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 21.70%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 59.73%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 0.3 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.25%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 1 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 94.52%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 3 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 64.60%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 69.98%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 1 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.86%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 3 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 92.16%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 6 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 70.20%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 75.29%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 0.3 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 2 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 86.01%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 1 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5
Experiment 3 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.39%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 3 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 77.14%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 3 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[52]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 79.33%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 3 mg/kg ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 87.30%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[31]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 87.40%	High HER2 expression (HER2 +++)
Method Description	Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the mammary fat pad of nu/nu mice in fragments that measured approximately 2x2 mm. MMTV-HER2 Fo5 mammary allograft tumors inoculated into CRL nu/nu mice aftersingle,then iv 10 mg/kg*1 ADC dosing on day 0.
In Vivo Model	Breast cancer model MMTV-HER2 Fo5

Experiment 1 Reporting the Activity Date of This ADC					[53]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.45 pM	Positive CCR4 expression (CCR4 +++/++)
Method Description	A comparison of the in vitro efficacy of CCR4-IL2 IT versus brentuximab to human CD25+CCR4+CD30+ Hut102/6TG cells was performed using a luminescent-based cell viability assay.
In Vitro Model	Cutaneous T cell lymphoma	HUT102/6TG cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.72 pM	High HER2 expression (HER2+++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 pM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian clear cell adenocarcinoma	TOV-21G cells		CVCL_3613
Experiment 3 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC4006 cells		CVCL_1269
Experiment 4 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2-9 pM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.01 pM	High HER2 expression (HER2+++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.9 pM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.1 pM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Normal	KE-97 cells		CVCL_3386

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3-11 pM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.26 pM	High HER2 expression (HER2+++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.34 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.9 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	19.3 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	30.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	48.2 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.51 pM	High HER2 expression (HER2+++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	57.8 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	112 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.3 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	51.6 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	107 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	29.6 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	54 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	62.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	65.2 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 5 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	65.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 6 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	201 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 7 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 8 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	30 pM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	34.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73.3 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	178 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	37.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	60 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	211 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	41.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	598 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.01 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	45.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73.2 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	165 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	46-57 pM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Negative MSLN expression (MSLN-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Childhood hepatocellular carcinoma	Hep 3B2.1-7 cells		CVCL_0326

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	46.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	67.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	371 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	47.9 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	92.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	426 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	48.9 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	50.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	51.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	50.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	53.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	54.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	50.8 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79.8 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	247 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	53.2 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	54.5 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	98.3 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	53.8 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	61.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	117 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	54.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	55.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	77.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	57.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	73 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	217 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	66.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	72.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.38 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	67.4 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	75.1 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	74.3 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	219 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	78.2 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	98.8 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	128 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	159 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 5 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	160 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 6 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	653 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 7 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	294 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79.7 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	189 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	114 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	156 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	158 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	130 pM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	131 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	137 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	153 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	156 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	170 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	184 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	167 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	968 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.37 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	186 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	262 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	335 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	218 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	225 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.29 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	228 pM	Positive GPC3 expression (GPC3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Childhood hepatocellular carcinoma	Hep 3B2.1-7 cells		CVCL_0326
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Negative GPC3 expression (GPC3-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	256 pM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Childhood acute monocytic leukemia	THP-1 cells		CVCL_0006
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	389 pM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 3 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	62.8 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Promyelocytic leukemia	NB-4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	356 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	405 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	370 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	509 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	485 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	740 pM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Childhood acute monocytic leukemia	THP-1 cells		CVCL_0006
Experiment 2 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 3 Reporting the Activity Date of This ADC					[27]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Positive CD123 expression (CD123+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Promyelocytic leukemia	NB-4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Negative CD70 expression (CD70-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Negative CD70 expression (CD70-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Positive CD70 expression (CD70+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Negative CD70 expression (CD70-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive CD70 expression (CD70+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Negative CD70 expression (CD70-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Positive CD70 expression (CD70+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Negative CD70 expression (CD70-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Positive CD70 expression (CD70+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Negative CD70 expression (CD70-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Positive CD70 expression (CD70+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 nM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.35 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC4006 cells		CVCL_1269
Experiment 3 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.38 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 4 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.68 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian clear cell adenocarcinoma	TOV-21G cells		CVCL_3613

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.03 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian clear cell adenocarcinoma	TOV-21G cells		CVCL_3613
Experiment 4 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.73 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 5 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.96 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC4006 cells		CVCL_1269
Experiment 6 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.17 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC4006 cells		CVCL_1269
Experiment 7 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.62 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 8 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	41.54 nM	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian clear cell adenocarcinoma	TOV-21G cells		CVCL_3613

Experiment 1 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 2 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.09 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 6 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.69 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.09 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18.47 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	14.56 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.82 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 2 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.23 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.23 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.29 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.6 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.78 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.4 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.5 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.7 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	100 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.31 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.34 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.19 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	14.84 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.52 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	47 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.22 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.05 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.09 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 41 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.23 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Positive HER2 expression (HER2+++/++)
Method Description	Anti-proliferation activities of the antibodies, drugs, and conjugates with regard tothe cancer cell lines were measured. The cells were plated in 96-well, tissue culture platesat 10,000 cells per well. After 24 hour incubation, the antibodies, drugs, and conjugateswere added in various concentrations. The number of viable cells after 72 hours were counted using SRB assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.64 nM	Positive HER2 expression (HER2+++/++)
Method Description	Anti-proliferation activities of the antibodies, drugs, and conjugates with regard tothe cancer cell lines were measured. The cells were plated in 96-well, tissue culture platesat 10,000 cells per well. After 24 hour incubation, the antibodies, drugs, and conjugateswere added in various concentrations. The number of viable cells after 72 hours were counted using SRB assay.    Click to Show/Hide
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.73 nM	Positive HER2 expression (HER2+++/++)
Method Description	Anti-proliferation activities of the antibodies, drugs, and conjugates with regard tothe cancer cell lines were measured. The cells were plated in 96-well, tissue culture platesat 10,000 cells per well. After 24 hour incubation, the antibodies, drugs, and conjugateswere added in various concentrations. The number of viable cells after 72 hours were counted using SRB assay.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.95 nM	Positive HER2 expression (HER2+++/++)
Method Description	Anti-proliferation activities of the antibodies, drugs, and conjugates with regard tothe cancer cell lines were measured. The cells were plated in 96-well, tissue culture platesat 10,000 cells per well. After 24 hour incubation, the antibodies, drugs, and conjugateswere added in various concentrations. The number of viable cells after 72 hours were counted using SRB assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 5 Reporting the Activity Date of This ADC					[59]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 33.3 nM	Negative HER2 expression (HER2-)
Method Description	Anti-proliferation activities of the antibodies, drugs, and conjugates with regard tothe cancer cell lines were measured. The cells were plated in 96-well, tissue culture platesat 10,000 cells per well. After 24 hour incubation, the antibodies, drugs, and conjugateswere added in various concentrations. The number of viable cells after 72 hours were counted using SRB assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 2 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Normal	KE-97 cells		CVCL_3386
Experiment 3 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 4 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.24 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 5 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.74 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Leukemia	SR cells		CVCL_1711
Experiment 6 Reporting the Activity Date of This ADC					[29]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.78 nM	Positive CCR7 expression (CCR7+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Chronic myelogenous leukemia	CML-T1 cells		CVCL_1126

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.4 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	79 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 0.08 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.54 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.25 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 44 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.21 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.09 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.96 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.6 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.6 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10-1.00 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10-1.00 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10-1.00 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10-1.00 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 nM	Positive IGF1R expression (IGF1R+++/++)
Method Description	MCF-7 cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.3 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.4 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.8 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.6 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	118.8 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.41 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 43 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM	Positive AXL expression (AXL+++/++)
Method Description	Briefly, cells were seeded into 96 well multi-well plates the day before drug treatment at 2500 cells per well. ADCs and controls were serially diluted and then added to the mw-96 plates. Cells were then incubated for 6 days at 37°C and 5% CO2.
In Vitro Model	Renal cell carcinoma	SN12C cells		CVCL_1705
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10 nM	Negative AXL expression (AXL-)
Method Description	Briefly, cells were seeded into 96 well multi-well plates the day before drug treatment at 2500 cells per well. ADCs and controls were serially diluted and then added to the mw-96 plates. Cells were then incubated for 6 days at 37°C and 5% CO2.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.76 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.05 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.12 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.13 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.27 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.1 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.7 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	61 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Positive AXL expression (AXL+++/++)
Method Description	Briefly, cells were seeded into 96 well multi-well plates the day before drug treatment at 2500 cells per well. ADCs and controls were serially diluted and then added to the mw-96 plates. Cells were then incubated for 6 days at 37°C and 5% CO2.
In Vitro Model	Renal cell carcinoma	SN12C cells		CVCL_1705
Experiment 2 Reporting the Activity Date of This ADC					[45]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 10 nM	Negative AXL expression (AXL-)
Method Description	Briefly, cells were seeded into 96 well multi-well plates the day before drug treatment at 2500 cells per well. ADCs and controls were serially diluted and then added to the mw-96 plates. Cells were then incubated for 6 days at 37°C and 5% CO2.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	High HER2 expression (HER2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Low HER2 expression (HER2-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.38 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.53 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	762.24 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.4 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	29.4 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	105 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	353 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	High HER2 expression (HER2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Low HER2 expression (HER2-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.18 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.39 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.48 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 52 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.29 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.79 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.9 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.41 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	31.6 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	233 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 nM	High HER2 expression (HER2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 nM	High HER2 expression (HER2+++/++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Low HER2 expression (HER2-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[40]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Low HER2 expression (HER2-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 nM	Positive HER2 expression (HER2+++/++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.21 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.65 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	796 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.22 nM	Positive CD33 expression (CD33+++/++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.23 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.31 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.95 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.24 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	SNU-5 cells		CVCL_0078
Experiment 2 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.35 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Hepatoma	Bel-7402 cells		CVCL_5492
Experiment 3 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.51 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	MKN45 cells		CVCL_0434
Experiment 4 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.1 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Adult hepatocellular carcinoma	HCCLM3 cells		CVCL_6832
Experiment 5 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.8 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1993 cells		CVCL_1512
Experiment 6 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.6 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	PC-9 cells		CVCL_B260
Experiment 7 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.5 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 8 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.9 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 CDX model cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.1 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Endocervical adenocarcinoma	QGY-7701 cells		CVCL_6859
Experiment 10 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	21.7 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Hepatocellular carcinoma	SMMC-7721 cells		CVCL_0534
Experiment 11 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	40.8 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Hepatoma	SK-HEP1 cells		CVCL_0525
Experiment 12 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	81.1 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Hepatoblastoma	Hep-G2 cells		CVCL_0027
Experiment 13 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	103.9 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung adenosquamous carcinoma	NCI-H596 cells		CVCL_1571
Experiment 14 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	109.4 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Childhood hepatocellular carcinoma	Hep 3B2.1-7 cells		CVCL_0326

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.24 nM	Positive PSMA expression (PSMA+++/++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.25 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.81 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	539.32 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 652.88 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.25 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23.9 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	30 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	30 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	77 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.26 nM	Positive CD20 expression (CD20+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.83 nM	Positive CD20 expression (CD20+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC4006 cells		CVCL_1269
Experiment 3 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.76 nM	Positive CD20 expression (CD20+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian clear cell adenocarcinoma	TOV-21G cells		CVCL_3613
Experiment 4 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	53.04 nM	Positive CD20 expression (CD20+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.26 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.3 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.51 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	37 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.3 nM	Positive CD79b expression (CD79b+++/++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.3 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.33 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.91 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.94 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.36 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.85 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	646 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	836 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.36 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (short reservation).
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.83 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (short reservation).
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 3 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.67 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (long reservation).
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.98 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (long reservation).
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.37 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.32 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.37 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.38 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.69 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 850 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.38 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.39 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.8 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	467.4 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	977.31 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.39 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.68 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	38.18 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.39 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.55 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.39 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.71 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.43 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.13 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.43 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.44 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.73 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	78.29 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	297.62 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.44 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.73 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.44 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.13 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	645 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.46 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.73 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.76 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.47 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.48 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.1 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.48 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.49 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.5-1.0 nM	Positive FucGM1 expression (FucGM1+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H187 cells		CVCL_1501
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.6-1.7 nM	Positive FucGM1 expression (FucGM1+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Small cell lung carcinoma	DMS-79 cells		CVCL_1178

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.52 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.03 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	123 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	580.3 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.53 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.53 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.56 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.04 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.13 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	749 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.57 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	38.7 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	626 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	734 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.57 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.57 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[60]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.59 nM	Positive MET expression (MET+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric adenocarcinoma	MKN45 cells		CVCL_0434

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.6 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.03 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.64 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.27 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.64 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.26 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.65 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.3 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.67 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.71 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.68 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.92 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	678.88 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 971.38 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.73 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.75 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.79 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	650.25 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	909.59 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.76 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.22 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	247.49 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.78 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.01 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.05 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.78 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.18 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.83 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.79 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.34 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 517.93 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.82 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.84 nM	Positive HER2 expression (HER2+++/++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells (Lenti-HER2 transfection)		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.86 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.58 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	180.13 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	329.21 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[61]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.88 nM	High HER2 expression (HER2 +++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.91 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.94 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	323.99 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.94 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.39 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	220.98 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.95 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.39 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.95 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.97 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.09 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	25.12 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	55.12 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.04 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.32 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.07 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.29 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	180.28 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.07 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.09 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.1 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.1 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.1 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.15 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.35 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.12 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.29 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.13 nM	Positive CD20 expression (CD20+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 2 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.29 nM	Positive CD20 expression (CD20+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC4006 cells		CVCL_1269
Experiment 3 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	37.3 nM	Positive CD20 expression (CD20+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 4 Reporting the Activity Date of This ADC					[54]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	39.68 nM	Positive CD20 expression (CD20+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Ovarian clear cell adenocarcinoma	TOV-21G cells		CVCL_3613

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.15 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.48 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.27 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	16.1 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.16 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.36 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.17 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.52 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.18 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.9 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	704.93 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.19 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.19 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.2 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.36 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	44.69 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	86.59 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.22 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.88 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.26 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.02 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.3 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267
Experiment 2 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.3 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.33 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.96 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.28 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	29.45 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.36 nM	Positive HER2 expression (HER2 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[25]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM	Negative HER2 expression (HER2 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.37 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	292.35 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.41 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.68 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	14.72 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.43 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.46 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.83 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.49 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.06 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.49 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H847 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung small cell carcinoma	NCI-H847 cells		CVCL_1596

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.51 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.89 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.91 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 4 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.78 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 5 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.1 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Renal carcinoma	A498 cells		CVCL_1056
Experiment 6 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	36.8 nM	Negative CD276 expression (CD276 -)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.58 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.7 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	166.11 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	253.89 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.83 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[61]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.88 nM	High HER2 expression (HER2 +++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.9 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.91 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.33 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	19.62 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.95 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2 nM	High HER2 expression (HER2+++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[34]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2 nM	High HER2 expression (HER2+++)
Method Description	The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO2, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.01 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.34 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.36 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H847 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung small cell carcinoma	NCI-H847 cells		CVCL_1596

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.64 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500.46 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.96 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.01 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.1 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.23 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.28 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.61 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[61]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.55 nM	High HER2 expression (HER2 +++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.77 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[47]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.81 nM	Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description	Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

Experiment 1 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.8 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	124 nM	Negative HER2 expression (HER2-)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 5 Reporting the Activity Date of This ADC					[58]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	300 nM	High HER2 expression (HER2+++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.54 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.3 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.52 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.88 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.05 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.52 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	40.99 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.22 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.96 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.73 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.97 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	20.99 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	29.39 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.99 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	35.58 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.35 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	95.43 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11.06 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	21.91 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	22.07 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	27.7 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	29.14 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[62]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	12 nM	Positive CD22 expression (CD22+++/++)
Method Description	Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.4 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	68.25 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	14.21 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.62 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	369.9 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	697.16 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.9 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	53.6 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Negative CD276 expression (CD276 -)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17.02 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	525.65 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[62]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18 nM	Positive CD22 expression (CD22+++/++)
Method Description	Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	21.89 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[62]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23 nM	Positive CD22 expression (CD22+++/++)
Method Description	Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	26.7 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H847 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung small cell carcinoma	NCI-H847 cells		CVCL_1596

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	27.27 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	33.94 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	38.9 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	148.1 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Negative CD276 expression (CD276 -)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

Experiment 1 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[57]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	80.4 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Pharyngeal squamous cell carcinoma	Detroit 562 cells		CVCL_1171
Experiment 2 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	321.5 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 3 Reporting the Activity Date of This ADC					[35]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 500 nM	Negative CD276 expression (CD276 -)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	80.98 nM	Positive CD276 expression (CD276 +++/++)
Method Description	Chimra IgG1 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
In Vitro Model	Breast ductal carcinoma	HCC38 cells		CVCL_1267

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 100 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	115.99 nM	Positive HER2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the NCI-N87 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	116.33 nM	Positive HER2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the NCI-N87 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[21]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	135.3 nM	Positive HER2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the NCI-N87 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	162.74 nM	Positive HER2 expression (HER2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	MDA-MB-435 cells		CVCL_0417
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	370.55 nM	Positive HER2 expression (HER2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	MDA-MB-435 cells		CVCL_0417

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	162.75 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 517.76 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	Negative HER2 expression (HER2-)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 5 Reporting the Activity Date of This ADC					[36]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 300 nM	High HER2 expression (HER2+++)
Method Description	Cells were plated at a density of 5,000 cells per well in black walled 96-well plate and allowed to adhere overnight in a humidified at mosphere of 5% CO2. CellTiter-Glo reagent was added to the wells at room temperature and the luminescent signal was measuredafter 10 min using a SpectraMax M5 plate reader.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	311.48 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	367.92 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	500.49 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	501.26 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 502.15 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 507.59 nM	High HER2 expression (HER2+++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Negative HER2 expression (HER2-)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[26]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 nM	Moderate HER2 expression (HER2 ++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-361 cells		CVCL_0620

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.15 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[28]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.6 ng/mL	Positive CD33 expression (CD33+++/++)
Method Description	The cells, at a predeterminedconcentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5CO2, serialdilutions of each test article (TA) were added to the cells. Cells were incubated with test articlesfor 72 hours, and viability was detected with CellTiter-Glo reagent.
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.8 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.88 ng/mL	Positive VEGFR expression (VEGFR+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Normal	HUVEC-C cells		CVCL_2959

Experiment 1 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1 ng/mL	Positive CD30 expression (CD30+++/++); Negative CD70 expression (CD70-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 2 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8 ng/mL	Positive CD30 expression (CD30+++/++); Low CD70 expression (CD70+)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Negative CD30 expression (CD30-); Negative CD70 expression (CD70-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Moderate CD30 expression (CD30++); Low CD70 expression (CD70+)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 5 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Positive CD70 expression (CD70+++/++); Negative CD30 expression (CD30-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 6 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Positive CD70 expression (CD70+++/++); Negative CD30 expression (CD30-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.8 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.64 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	14 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	27 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	30 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 7 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	35 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 8 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	251 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	90 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	324 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	95 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	635 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 5 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132

Experiment 1 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.9 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	PC3-MM2 cells		CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.9 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[32]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 400 ug/mL	Negative IL13 expression (IL13-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung large cell carcinoma	NCI-H460 cells		CVCL_0459

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.92 ng/mL	Positive VEGFR expression (VEGFR+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Normal	HUVEC-C cells		CVCL_2959

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.36 ng/mL	Positive IL13 expression (IL13+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7 ng/mL	Positive CD70 expression (CD70+++/++); Negative CD30 expression (CD30-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 2 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Negative CD30 expression (CD30-); Negative CD70 expression (CD70-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Moderate CD30 expression (CD30++); Low CD70 expression (CD70+)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Hodgkin lymphoma	L-428 cells		CVCL_1361
Experiment 4 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Positive CD70 expression (CD70+++/++); Negative CD30 expression (CD30-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 5 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Positive CD30 expression (CD30+++/++); Low CD70 expression (CD70+)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC					[64]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Positive CD30 expression (CD30+++/++); Negative CD70 expression (CD70-)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.4 ng/mL	Positive VEGFR expression (VEGFR+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Normal	HUVEC-C cells		CVCL_2959

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	19 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Osteosarcoma	U2OS cells		CVCL_0042
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	289 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	671 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	21 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	922 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung non-small cell carcinoma	HCC2429 cells		CVCL_5132

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	83 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	137 ng/mL	Positive VEGFR expression (VEGFR+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Normal	HUVEC-C cells		CVCL_2959

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	259 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	560 ng/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	High HER2 expression (HER2+++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast inflammatory carcinoma	KPL-4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[23]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	High HER2 expression (HER2 +++)
Method Description	Cell-based in vitro assays are used to measure viability (proliferation), cytotoxicity,and induction of apoptosis of the ADC of the invention. Culturing the cells for a period from about 6 hours to about 5 days and measuring cell viability.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Acute megakaryoblastic leukemia	CMK-11-5 cells		CVCL_0217
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Chronic myeloid leukemia	KU812 cells		CVCL_0379
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Lung small cell carcinoma	NCI-H526 cells		CVCL_1569
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[56]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 uM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[16]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive NOTCH3 expression (NOTCH3+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[63]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0 ug/mL	Positive VEGFR expression (VEGFR+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Normal	HUVEC-C cells		CVCL_2959

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.21 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.2 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.64 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.78 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[65]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.7 ug/mL	Positive CD70 expression (CD70 +++/++)
Method Description	786-O cells were plated at 30K cells/well overnight at 37°C in RPMI Media assuggested by ATCC (+ 10% HI FBS). Cells were stimulated with ADCs for 2, 6, or 24 hours at 37°C.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.26 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.89 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.56 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.5 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.1 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	16.84 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	18.7 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[39]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	25.67 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 nM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 nM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 nM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive MSLN expression (MSLN+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	45 nM	Negative MSLN expression (MSLN-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 nM	High HER2 expression (HER2 +++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO2 by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	High HER2 expression (HER2 +++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO2 by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.9 nM	Moderate HER2 expression (HER2++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO2 by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.11 nM	High HER2 expression (HER2 +++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO2 by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532
Experiment 2 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Moderate HER2 expression (HER2++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO2 by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[44]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	High HER2 expression (HER2 +++)
Method Description	Cell viability was determined after -72 h -incubation with different concentrations of conjugates at 37°C and 5% CO2 by measurement of fixed andpermeabilized cells with an ant-BrdU-HRP antibody.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.19 nM	Positive CD70 expression (CD70+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.54 nM	Negative CD70 expression (CD70-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544
Experiment 3 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.4 nM	Negative CD70 expression (CD70-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.21 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.22 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 nM	Positive FucGM1 expression (FucGM1+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Small cell lung carcinoma	DMS-79 cells		CVCL_1178
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 nM	Positive FucGM1 expression (FucGM1+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H187 cells		CVCL_1501
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative FucGM1 expression (FucGM1-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.33 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4 nM	Positive FucGM1 expression (FucGM1+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H187 cells		CVCL_1501
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4 nM	Positive FucGM1 expression (FucGM1+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Small cell lung carcinoma	DMS-79 cells		CVCL_1178
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative FucGM1 expression (FucGM1-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.42 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.43 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.45 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.49 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.52 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.53 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.59 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.59 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.63 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.68 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.71 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.71 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.71 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.72 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.79 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.83 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.85 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.85 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.87 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.95 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.01 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.1 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.11 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.35 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.4 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.6 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.7 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.8 nM	Positive FucGM1 expression (FucGM1+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma	NCI-H187 cells		CVCL_1501
Experiment 2 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.1 nM	Positive FucGM1 expression (FucGM1+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Small cell lung carcinoma	DMS-79 cells		CVCL_1178
Experiment 3 Reporting the Activity Date of This ADC					[66]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative FucGM1 expression (FucGM1-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.07 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.1 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.4 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.59 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.4 nM	Positive TROP2 expression (TROP2 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Breast squamous cell carcinoma	HCC1806 cells		CVCL_1258
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10000 nM	Negative TROP2 expression (TROP2 -)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	NCI-H23 cells		CVCL_1547

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.6 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 nM	Negative FucGM1 expression (FucGM1-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	6.9 nM	Negative FucGM1 expression (FucGM1-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	44 nM	Negative FucGM1 expression (FucGM1-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.7 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.52 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.6 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	6.5 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.3 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.4 nM	Negative FucGM1 expression (FucGM1-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544
Experiment 2 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	16.27 nM	Negative FucGM1 expression (FucGM1-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.9 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.1 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.3 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.4 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	14.4 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	21 nM	Positive TROP2 expression (TROP2 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Breast squamous cell carcinoma	HCC1806 cells		CVCL_1258
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10000 nM	Negative TROP2 expression (TROP2 -)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Lung adenocarcinoma	NCI-H23 cells		CVCL_1547

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	52.5 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[55]
Efficacy Data	Half Maximal Effective Concentration (EC50)	60 nM	Negative MSLN expression (MSLN-)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	63.5 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 133 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[33]
Efficacy Data	Half Maximal Effective Concentration (EC50)	178.8 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	307 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	11 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	25 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 12 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	8 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	26 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	29 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	29 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 5 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 6 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 7 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 9 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 10 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 11 Reporting the Activity Date of This ADC					[67]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.89 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.13 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.18 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.72 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.74 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	6.7 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.09 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.3 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	11.56 ng/mL	Positive EGFR expression (EGFR +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-520 cells		CVCL_1355

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.7 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	14.3 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	18.17 ng/mL	Positive EGFR expression (EGFR +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-520 cells		CVCL_1355

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	19.01 ng/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-520 cells		CVCL_1355
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	47.74 ug/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	29.21 ng/mL	Positive EGFR expression (EGFR +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-520 cells		CVCL_1355

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	32.94 ng/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Esophageal squamous cell carcinoma	KYSE-520 cells		CVCL_1355
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	65.11 ug/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	42.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	DU145 cells		CVCL_0105

Experiment 1 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	53.9 ng/mL	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	DU145 cells		CVCL_0105

Experiment 1 Reporting the Activity Date of This ADC					[37]
Efficacy Data	Half Maximal Effective Concentration (EC50)	68.4 ng/mL	Positive HER2 expression (HER2+++/++)
Method Description	The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	75.6 ng/mL	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	DU145 cells		CVCL_0105

Experiment 1 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	95.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	DU145 cells		CVCL_0105

Experiment 1 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	103 ng/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	183 ng/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 CDX model cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0 ug/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082
Experiment 4 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0 ug/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082
Experiment 5 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0 ug/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Normal	HEK293 cells		CVCL_0045

Experiment 1 Reporting the Activity Date of This ADC					[68]
Efficacy Data	Half Maximal Effective Concentration (EC50)	199.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	DU145 cells		CVCL_0105

Experiment 1 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	274 ng/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	507 ng/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 CDX model cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0 ug/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082
Experiment 4 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0 ug/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Gastric signet ring cell adenocarcinoma	NUGC-4 cells		CVCL_3082
Experiment 5 Reporting the Activity Date of This ADC					[69]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0 ug/mL	Positive CLDN18.2 expression (CLDN18.2+++/++)
Method Description	Cells were counted and seeded in 96 well plates at densities of 2600-3600 cells/well in 100 ul of cell culture medium, A duplicate plate was generated for a day 0 measurement and all plates were incubated in a tissue culture incubator at 37°C with 5% CO2 overnight. Following this incubation, 50 ul/well of Cell titer Glo reagent was added to the day 0 plates, which were then shaken gently for 10 min and the resulting luminescence intensity was measured.    Click to Show/Hide
In Vitro Model	Normal	HEK293 cells		CVCL_0045

Experiment 1 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	611.3 ng/mL	Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC					[20]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.36 ug/mL	High NECTIN4 expression (NECTIN4 +++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.63 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.21 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.21 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.26 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.67 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.32 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.47 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.87 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.99 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.08 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.02 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.18 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.56 ug/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.93 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.07 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.03 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.45 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	23 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	55 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.57 ug/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	14.3 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	18.38 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.35 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	19.58 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	21.07 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.63 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20.83 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	24.42 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	22.17 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	27.86 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	28.49 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	28.79 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	28.51 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	29.16 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Negative CD74 expression (CD74 -)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-6 cells		CVCL_2206
Experiment 3 Reporting the Activity Date of This ADC					[70]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 30 ug/mL	Positive CD74 expression (CD74 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
In Vitro Model	T lymphocytic leukemia	HuT 78 cells		CVCL_0337

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	30.43 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	30.9 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	32.47 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	31.06 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	42.07 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	49.33 ug/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	50.77 ug/mL	Positive HER3 expression (HER3 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	83.36 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[18]
Efficacy Data	Half Maximal Effective Concentration (EC50)	101.65 ug/mL	Positive CD276 expression (CD276 +++/++)
Method Description	Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559

Experiment 1 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Tumor Growth lnhibition value (TGl)	< 5%	Positive CALU-6 expression (CALU-6+++/++)
Method Description	mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 1 mg/kg.
In Vivo Model	NSCLC CALU-6 (lung cancer) model
Experiment 2 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Tumor Growth lnhibition value (TGl)	≈ 20%
Method Description	mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 1 mg/kg.
In Vivo Model	MDA-MB-231 (TNBC) model
Experiment 3 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Tumor Growth lnhibition value (TGl)	≈ 30%	Positive CALU-6 expression (CALU-6+++/++)
Method Description	mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
In Vivo Model	NSCLC CALU-6 (lung cancer) model
Experiment 4 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CALU-6 expression (CALU-6+++/++)
Method Description	mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
In Vivo Model	NSCLC CALU-6 (lung cancer) model
Experiment 5 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 3 mg/kg.
In Vivo Model	MDA-MB-231 (TNBC) model
Experiment 6 Reporting the Activity Date of This ADC					[71]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%
Method Description	mAb-vcMMAE (DAR of 4) was examined in a NSCLC CALU-6 (lung cancer) model after dosing at Q7dx3 at 6 mg/kg.
In Vivo Model	MDA-MB-231 (TNBC) model

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	< 30%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) was subcutaneously inoculated at a dose of 5x106 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 7, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	SU-DHL-8 (ATCC) female SCID mouse model
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 9, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	OCI-LY7 (DSMZ) female SCID mouse model
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 11, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 (DSMZ) female SCID mouse model
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 90%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 11, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 (DSMZ) female SCID mouse model
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 9, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	OCI-LY7 (DSMZ) female SCID mouse model
Experiment 6 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) was subcutaneously inoculated at a dose of 5x106 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 7, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	SU-DHL-8 (ATCC) female SCID mouse model

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 1 nM	Positive CD37 expression (CD37+++/++)
Method Description	human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) , 5x10-cells/100 ML/well , IMDM medium , hmnAb-H11L11-DXd was added to the cells such that the final concentrations were from 0.0064 nM to 20 nM. The cells were cultured under conditions of 37°C. and 5% CO2 for 6 days, and thereafter, the number of live cells was measured.
In Vitro Model	Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma	OCI-LY7 cells		CVCL_1881

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	< 30%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) was subcutaneously inoculated at a dose of 5x106 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 7, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	SU-DHL-8 (ATCC) female SCID mouse model
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 9, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	OCI-LY7 (DSMZ) female SCID mouse model
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 11, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 (DSMZ) female SCID mouse model
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 90%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 11, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 (DSMZ) female SCID mouse model
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 99%	Positive CD37 expression (CD37+++/++)
Method Description	CD37- positive human chronic lymphocytic leukemia cell line JVM-3 (DSMZ) was subcutaneously inoculated at a dose of 3x106 cells to the right flank region of each female SCID mouse (Day 0). On Day 13, the mice were randomly grouped. On the day of grouping, hmAb-H541L11-DXd was intravenously administered to the tail of each mouse at 1 mg/kg.
In Vivo Model	JVM-3 (DSMZ) female SCID mouse model
Experiment 6 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 9, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	OCI-LY7 (DSMZ) female SCID mouse model
Experiment 7 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) was subcutaneously inoculated at a dose of 5x106 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 7, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	SU-DHL-8 (ATCC) female SCID mouse model
Experiment 8 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37- positive human chronic lymphocytic leukemia cell line JVM-3 (DSMZ) was subcutaneously inoculated at a dose of 3x106 cells to the right flank region of each female SCID mouse (Day 0). On Day 13, the mice were randomly grouped. On the day of grouping, hmAb-H541L11-DXd was intravenously administered to the tail of each mouse at 3 mg/kg.
In Vivo Model	JVM-3 (DSMZ) female SCID mouse model
Experiment 9 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37- positive human follicular lymphoma cell line DOHH-2 (DSMZ) was subcutaneously inoculated at a dose of 1x106 cells to the right flank region of each female SCID mouse (Day 0). On Day 21, the mice were randomly grouped. On the day of grouping, hmAb-H541L11-DXd was intravenously administered to the tail of each mouse at 1 mg/kg.
In Vivo Model	DOHH-2 (DSMZ) female SCID mouse model
Experiment 10 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37- positive human follicular lymphoma cell line DOHH-2 (DSMZ) was subcutaneously inoculated at a dose of 1x106 cells to the right flank region of each female SCID mouse (Day 0). On Day 21, the mice were randomly grouped. On the day of grouping, hmAb-H541L11-DXd was intravenously administered to the tail of each mouse at 3 mg/kg.
In Vivo Model	DOHH-2 (DSMZ) female SCID mouse model

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 0.7 nM	Positive CD37 expression (CD37+++/++)
Method Description	human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) , 5x10-cells/100 ML/well , IMDM medium , hmAbH541L11-DXd was added to the cells such that the final concentrations were from 0.0064 nM to 20 nM. The cells were cultured under conditions of 37°C. and 5% CO2 for 6 days, and thereafter, the number of live cells was measured.
In Vitro Model	Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma	OCI-LY7 cells		CVCL_1881

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	< 30%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) was subcutaneously inoculated at a dose of 5x106 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 7, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	SU-DHL-8 (ATCC) female SCID mouse model
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 9, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	OCI-LY7 (DSMZ) female SCID mouse model
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 11, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 (DSMZ) female SCID mouse model
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 90%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 11, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 (DSMZ) female SCID mouse model
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 9, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	OCI-LY7 (DSMZ) female SCID mouse model
Experiment 6 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) was subcutaneously inoculated at a dose of 5x106 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 7, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	SU-DHL-8 (ATCC) female SCID mouse model

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 0.7 nM	Positive CD37 expression (CD37+++/++)
Method Description	human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) , 5x10-cells/100 ML/well , IMDM medium hmAb-H551L11-DXd was added to the cells such that the final concentrations were from 0.0064 nM to 20 nM. The cells were cultured under conditions of 37°C. and 5% CO2 for 6 days, and thereafter, the number of live cells was measured.
In Vitro Model	Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma	OCI-LY7 cells		CVCL_1881

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	< 30%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) was subcutaneously inoculated at a dose of 5x106 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 7, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	SU-DHL-8 (ATCC) female SCID mouse model
Experiment 2 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 9, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	OCI-LY7 (DSMZ) female SCID mouse model
Experiment 3 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 50%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 11, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 (DSMZ) female SCID mouse model
Experiment 4 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 90%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 11, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	WSU-DLCL2 (DSMZ) female SCID mouse model
Experiment 5 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was subcutaneously inoculated at a dose of 1x107 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 9, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	OCI-LY7 (DSMZ) female SCID mouse model
Experiment 6 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Tumor Growth lnhibition value (TGl)	> 100%	Positive CD37 expression (CD37+++/++)
Method Description	CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) was subcutaneously inoculated at a dose of 5x106 cells to the right flank region of each five or six-week-old female SCID mouse (Day 0). On Day 7, the mice were randomly grouped. On the day of grouping, the antibodydrug conjugates hmAb-H11L11-DXd was intravenously administered at a dose of 1 mg/kg to the tail of each mouse. An antibody-drug conjugate (hmAb-IgG1-DXd) produced using human IgG was administered as a negative control at a dose of 3 mg/kg in the same manner as above. The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers, and the volume of the tumor was then calculated.    Click to Show/Hide
In Vivo Model	SU-DHL-8 (ATCC) female SCID mouse model

Experiment 1 Reporting the Activity Date of This ADC					[72]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	≈ 2 nM	Positive CD37 expression (CD37+++/++)
Method Description	human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) , 5x10-cells/100 ML/well , IMDM medium, hmAbH11laL11-DXd was added to the cells such that the final concentrations were from 0.0064 nM to 20 nM. The cells were cultured under conditions of 37°C. and 5% CO2 for 6 days, and thereafter, the number of live cells was measured.
In Vitro Model	Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma	OCI-LY7 cells		CVCL_1881

Experiment 1 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Tumor Growth lnhibition value (TGl)	55.29%
Method Description	HN02-L (5 mg/kg): BEL7402 (2×106) cells were injected subcutaneously into the right side of BALB/C nude mice to establish a hepatocellular carcinoma xenograft model. After the mean tumor volume reached 50-100 mm3, the tumor-bearing mice were divided randomly into 5 groups (eight mice/group). TG7 (5 mg/kg), HN02-L (5 mg/kg), HN02-H (10 mg/kg), or saline were injected intravenously every 3 days, and the positive group was treated with the drug sorafenib (20 mg/kg) by gavage daily for 3 w. Body weights and tumor volumes were measured periodically, and tumor volume was calculated using the formula V=LW2 /2 (L: long diameter of the tumor, W: short diameter of the tumor in the vertical direction). All mice were executed on day 21 of treatment, and tumors were excised for subsequent analysis.    Click to Show/Hide
In Vivo Model	BEL7402 hepatocellular carcinoma model
Experiment 2 Reporting the Activity Date of This ADC					[73]
Efficacy Data	Tumor Growth lnhibition value (TGl)	70.25%
Method Description	HN02-H (10 mg/kg): BEL7402 (2×106) cells were injected subcutaneously into the right side of BALB/C nude mice to establish a hepatocellular carcinoma xenograft model. After the mean tumor volume reached 50-100 mm3, the tumor-bearing mice were divided randomly into 5 groups (eight mice/group). TG7 (5 mg/kg), HN02-L (5 mg/kg), HN02-H (10 mg/kg), or saline were injected intravenously every 3 days, and the positive group was treated with the drug sorafenib (20 mg/kg) by gavage daily for 3 w. Body weights and tumor volumes were measured periodically, and tumor volume was calculated using the formula V=LW2 /2 (L: long diameter of the tumor, W: short diameter of the tumor in the vertical direction). All mice were executed on day 21 of treatment, and tumors were excised for subsequent analysis.    Click to Show/Hide
In Vivo Model	BEL7402 hepatocellular carcinoma model

Experiment 1 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Tumor Growth lnhibition value (TGl)	62.02%	Positive B7H3 expression (B7H3+++/++)
Method Description	In the Hep-3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	Hep-3 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Tumor Growth lnhibition value (TGl)	62.02%	Positive B7H3 expression (B7H3+++/++)
Method Description	In the Hep-3 xenograft model, the ADCs were administered at 5 mg/kg (once, IV).
In Vivo Model	Hep-3 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	. nM	Negative B7H3 expression (B7H3-)
Method Description	5000 CHO-K1 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
In Vitro Model	Normal	CHO-K1 cells		CVCL_0214
Experiment 2 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.77 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	5000 CHO-K1-B7-H3 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
In Vitro Model	Normal	CHO-K1-B7-H3 cells		CVCL_0214
Experiment 3 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.77 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	5000 CHO-K1-B7-H3 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
In Vitro Model	Normal	CHO-K1-B7-H3 cells		CVCL_0214
Experiment 4 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	68.75 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	5000 Calu-6 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236
Experiment 5 Reporting the Activity Date of This ADC					[74]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	68.75 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	5000 Calu-6 cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with ADC15 (4x the first top concentration at 200 ug/mL) for 7 days.
In Vitro Model	Lung adenocarcinoma	Calu-6 cells		CVCL_0236

Experiment 1 Reporting the Activity Date of This ADC					[75]
Efficacy Data	Tumor Growth lnhibition value (TGl)	95.31%
Method Description	Discovered Using Cell Line-derived IGROV1 tumor xenograft model in 151-C-LOCK-D5 1.5 mg/kg.
In Vivo Model	IGROV1 tumor xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[75]
Efficacy Data	Tumor Growth lnhibition value (TGl)	100%
Method Description	Discovered Using Cell Line-derived IGROV1 tumor xenograft model in 151-C-LOCK-D5 1.5 mg/kg.
In Vivo Model	IGROV1 tumor xenograft model
Experiment 3 Reporting the Activity Date of This ADC					[75]
Efficacy Data	Tumor Growth lnhibition value (TGl)	100%
Method Description	Discovered Using Cell Line-derived IGROV1 tumor xenograft model in 151-C-LOCK-D5 1.5 mg/kg.
In Vivo Model	IGROV1 tumor xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[75]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.35 nM	High IGROV1 expression (IGROV1 +++)
Method Description	IC50 Values (nM) of anti-FOLR1-151-C-LOCK-D5 and their corresponding controls in Human Tumor Cells IGROV1
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[75]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	45 nM	Low SKOV-3 expression ( SKOV-3+)
Method Description	IC50 Values (nM) of anti-FOLR1-151-C-LOCK-D5 and their corresponding controls in Human Tumor Cells SKOV-3
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[76]
Efficacy Data	The ADC concentration required to produce 10,000 pg/mL TNF-alpha was evaluated.	> 1000 nM	Positive CLDN6 expression (CLDN6+++/++)
Method Description	ExL1A2 was tested in co-culture system consisting of Human peripheral blood mononuclear cells (PBMCs) and NUGC33 cells, with the concentration range of 5.5 uM to 0.97 uM,TNF-a and INF-y productions were measured.
In Vitro Model	Normal; Gastric adenocarcinoma	PBMC cells; NUGC3 cells		.;CVCL_1612
Experiment 2 Reporting the Activity Date of This ADC					[76]
Efficacy Data	The ADC concentration required to produce 10,000 pg/mL INF-Gamma was evaluated.	100- 1000 nM	Positive CLDN6 expression (CLDN6+++/++)
Method Description	ExL1A2 was tested in co-culture system consisting of Human peripheral blood mononuclear cells (PBMCs) and NUGC33 cells, with the concentration range of 5.5 uM to 0.97 uM,TNF-a and INF-y productions were measured.
In Vitro Model	Normal; Gastric adenocarcinoma	PBMC cells; NUGC3 cells		.;CVCL_1612

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	72.57&#17714.06 mm3	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.    Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	124.95&#17710.32 mm3	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.    Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0473 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.07 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	121.05&#17712.02 mm3	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.    Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	192&#17769.04 mm3	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.    Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0837 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.2201 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	135.24&#17719.3 mm3	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.    Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	234.79&#17774.12 mm3	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.    Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0729 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0981 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	220.38&#17720.41 mm3	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.    Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	632.99&#177 70.34 mm3	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.    Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0657 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0994 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	245.33&#17716.58 mm3	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.    Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	319.79&#17789.97 mm3	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.    Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0543 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0801 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	304.9&#17727.25 mm3	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.    Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	866.94&#177119.56 mm3	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.    Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0608 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0783 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	343.65&#17736.11 mm3	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.    Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	928.09&#177103.94 mm3	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.    Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.1154 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.3107 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	349.91&#17738.36 mm3	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.    Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	820.06&#177131.53 mm3	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.    Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0572 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.088 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	366.45&#17731.56 mm3	Moderate nectin-4 expression (nectin-4++)
Method Description	Female NSG mice between 5-6 weeks of age were injected subcutaneously withMDA-MB-468 cells with moderate nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 71.    Click to Show/Hide
In Vivo Model	MDAMB468 xenograft model
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Mean tumor colume&#177SEM	993.45&#177189.2 mm3	High nectin-4 expression (nectin-4 +++)
Method Description	Immune compromised female mice between 5-8 weeks of age with weight 18-20 grams were implanted unilaterally on the right flank with UM-UC-3 Nectin4 clone F7 cells with high nectin-4 expression, when tumors reached appproximately 150-250 mm^3, animals were matched by tumor volume into treatment or controls groups and dosing initiated (Day 0, n=8 per group). The test articles were given at a single dose (2 mg/kg) formulated with 5% dextrose. Tumors were measured biweekly until Day 40.    Click to Show/Hide
In Vivo Model	UMUC3 Nectin-4 clone F7 xenograft model

Experiment 1 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0553 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in NCI H1781 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H1781 cells		CVCL_1494
Experiment 2 Reporting the Activity Date of This ADC					[77]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0825 nM	Positive nectin-4 expression (nectin-4+++/++)
Method Description	ADCs were tested in T24-human nectin-4 clone 108 cells, and were added at final working concentration from 200 nM, 1:4 serially diluted in culture medium for 5 days.
In Vitro Model	Bladder carcinoma	T24-human nectin-4 clone cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC71)	11.5 nM
Method Description	Tumor cells (A375) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Amelanotic melanoma	A375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	2 nM
Method Description	Tumor cells (Colo853) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	Colo853 cells		CVCL_2003
Experiment 3 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	7.5 nM	Moderate MELTF expression (MELTF++)
Method Description	Tumor cells (A2058) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 4 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	14.7 nM
Method Description	Tumor cells (IGR37) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	IGR37 cells		CVCL_2075
Experiment 5 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC57)	1.8 nM
Method Description	Tumor cells (SK-MEL-5) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.4 nM
Method Description	Tumor cells (SK-MEL-28) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC70)	0.028 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC69)	0.036 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 29%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC69)	12 nM
Method Description	Tumor cells (A375) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Amelanotic melanoma	A375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	5 nM	Moderate MELTF expression (MELTF++)
Method Description	Tumor cells (A2058) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	52 nM
Method Description	Tumor cells (IGR37) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	IGR37 cells		CVCL_2075
Experiment 4 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC62)	68 nM
Method Description	Tumor cells (Colo853) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	Colo853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC55)	14 nM
Method Description	Tumor cells (SK-MEL-5) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	32 nM
Method Description	Tumor cells (SK-MEL-28) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC68)	0.04 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 28%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC68)	0.7 nM
Method Description	Tumor cells (A375) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Amelanotic melanoma	A375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	0.3 nM	Moderate MELTF expression (MELTF++)
Method Description	Tumor cells (A2058) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	2 nM
Method Description	Tumor cells (IGR37) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	IGR37 cells		CVCL_2075
Experiment 4 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC61)	0.2 nM
Method Description	Tumor cells (Colo853) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	Colo853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC54)	0.05 nM
Method Description	Tumor cells (SK-MEL-5) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.3 nM
Method Description	Tumor cells (SK-MEL-28) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC67)	0.0098 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 27%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC67)	2 nM
Method Description	Tumor cells (A375) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Amelanotic melanoma	A375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	1 nM	Moderate MELTF expression (MELTF++)
Method Description	Tumor cells (A2058) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	16 nM
Method Description	Tumor cells (IGR37) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	IGR37 cells		CVCL_2075
Experiment 4 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC60)	2 nM
Method Description	Tumor cells (Colo853) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	Colo853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC53)	0.4 nM
Method Description	Tumor cells (SK-MEL-5) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3 nM
Method Description	Tumor cells (SK-MEL-28) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC66)	0.046 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 26%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC66)	0.5 nM
Method Description	Tumor cells (A375) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Amelanotic melanoma	A375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	0.5 nM	Moderate MELTF expression (MELTF++)
Method Description	Tumor cells (A2058) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	1.3 nM
Method Description	Tumor cells (IGR37) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Melanoma	IGR37 cells		CVCL_2075
Experiment 4 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC59)	0.7 nM
Method Description	Tumor cells (Colo853) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	Colo853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC52)	0.2 nM
Method Description	Tumor cells (SK-MEL-5) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC					[78]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.4 nM
Method Description	Tumor cells (SK-MEL-28) were incubated with CD228 ADCs for 96-144 hours at 37°C. Cell viability was measured using Cell Titer Glo according to manufacturer'sinstructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC65)	0.043 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 25%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC64)	0.029 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 24%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC63)	0.029 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 23%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC62)	0.022 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 22%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC61)	0.008 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 21%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC60)	0.004 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 20%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC59)	. .	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 19%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC58)	. .	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 18%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC57)	0.029 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 17%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Half Maximal inhibitory Concentration (lC57)	0.144 nM	Positive HER2 expression (HER2+++/++)
Method Description	Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC12owas calculated after reading the fluorescence data.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	0.312 nM	Positive HER2 expression (HER2+++/++)
Method Description	Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC11owas calculated after reading the fluorescence data.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC57)	> 75000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	16000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	20000 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	40 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 5 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	120 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 6 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1400 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	0.495 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 16%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 19000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	79 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5100 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	21000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	100 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5000 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	25000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	29000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	15 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 4 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	170 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 5 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8100 ng/ml	Moderate 5T4 expression (5T4++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/5T4 (a high 5t4 expressor) and MDA-MB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 29000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 39000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	79 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 4 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	81 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 5 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5500 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7100 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 36000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	79 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3300 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 41000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	100 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	17000 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 43000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	98 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	30000 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 45000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 83000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	14 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 4 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	160 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 5 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13000 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	> 75000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	160 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	32000 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC56)	84000 ng/ml	Negative 5T4 expression (5T4-)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	15 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 3 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	270 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Amelanotic melanoma	MDA?MB?435 cells (5t4+)		CVCL_0417
Experiment 4 Reporting the Activity Date of This ADC					[81]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	36000 ng/ml	Positive 5T4 expression (5T4+++/++)
Method Description	The 5T4 Cys-mutated mcMMAD and vcMMAD ADCs were each able to inhibit the growth of the 5T4 expressing cell lines MDAMB435/57T4 (a high 514 expressor) and MDAMB-468 (a HER2 resistant cell line with moderate 5T4 expression).
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC55)	0.05 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 15%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Half Maximal inhibitory Concentration (lC55)	16.1 nM	Positive HER2 expression (HER2+++/++)
Method Description	Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC10owas calculated after reading the fluorescence data.
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC54)	0.588 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 14%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC53)	0.034 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 13%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC52)	0.114 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 12%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC51)	0.027 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 11%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Half Maximal inhibitory Concentration (lC51)	0.113 nM	Positive HER2 expression (HER2+++/++)
Method Description	Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC6owas calculated after reading the fluorescence data.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.03 pM	Positive CD45 expression (CD45+++/++)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	Acute erythroid leukemia	OCIM1 cells		CVCL_2149
Experiment 2 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.213 pM	Positive CD45 expression (CD45+++/++)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 3 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 6000 pM	Negative CD45 expression (CD45-)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	Normal	293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.052 pM	Positive CD45 expression (CD45+++/++)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 2 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.096 pM	Positive CD45 expression (CD45+++/++)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	Acute erythroid leukemia	OCIM1 cells		CVCL_2149
Experiment 3 Reporting the Activity Date of This ADC					[82]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 6000 pM	Negative CD45 expression (CD45-)
Method Description	Cells at 0.5 × 105/mL were cultured for 5 days in mAb or ADC or medium (in triplicate wells) in wells of flat-bottom 96-well plates. PrestoBlue Cell Viability reagent (Thermo Fisher Scientific) was added and incubated for 1.5 h. Fluorescence intensity from each well was detected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesbury, UK) using excitation filter of 560-10 and emission filter of 590-10, and gain at 1,500. Data were plotted using GraphPad Prism software, and sigmoid dose-response non-linear regression was carried out to determine IC50 values.    Click to Show/Hide
In Vitro Model	Normal	293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[83]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.174 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC					[83]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on H2110
In Vitro Model	Lung non-small cell carcinoma	H2110 cells		CVCL_1530
Experiment 3 Reporting the Activity Date of This ADC					[83]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	50 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OVCAR-3
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[83]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	398 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OV90
In Vitro Model	Adenocarcinoma of ovary, Ovarian adenocarcinoma	OV90 cells		CVCL_3768

Experiment 1 Reporting the Activity Date of This ADC					[83]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.174 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on Jeg3
In Vitro Model	Gestational choriocarcinoma	Jeg3 cells		CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC					[83]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on H2110
In Vitro Model	Lung non-small cell carcinoma	H2110 cells		CVCL_1530
Experiment 3 Reporting the Activity Date of This ADC					[83]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	50 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OVCAR-3
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465
Experiment 4 Reporting the Activity Date of This ADC					[83]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	398 pM	High FRa expression (FRa +++)
Method Description	A Cell line test on OV90
In Vitro Model	Adenocarcinoma of ovary, Ovarian adenocarcinoma	OV90 cells		CVCL_3768

Experiment 1 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	. nM	Negativeher2 expression (her2-)
Method Description	MDA-MB-468 at 100uL/well (1000 to 10000 cells), 0.9mg/ml ADCs (10, 3.3, 1.1, 0.37, 0.12, 0.041, 0.014, 0.0046, 0.0015, and 0.00051 nM) were added and incubated for 72 to 120 h, then 100 L of CellTiter Glo reagent was added into each well, a shaker shook for 2 min, followed by standing in a dark place at rt for 10 min, and the relative light unit (RLU) was measured with a Cytation 3 microplate reader.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.1076 nM	Positive her2 expression (her2+++/++)
Method Description	SK-BR-3 at 100uL/well (1000 to 10000 cells), 0.9mg/ml ADCs (10, 3.3, 1.1, 0.37, 0.12, 0.041, 0.014, 0.0046, 0.0015, and 0.00051 nM) were added and incubated for 72 to 120 h, then 100 L of CellTiter Glo reagent was added into each well, a shaker shook for 2 min, followed by standing in a dark place at rt for 10 min, and the relative light unit (RLU) was measured with a Cytation 3 microplate reader.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.4355 nM	Positive her2 expression (her2+++/++)
Method Description	HCC1954 at 100uL/well (1000 to 10000 cells), 0.9mg/ml ADCs (10, 3.3, 1.1, 0.37, 0.12, 0.041, 0.014, 0.0046, 0.0015, and 0.00051 nM) were added and incubated for 72 to 120 h, then 100 L of CellTiter Glo reagent was added into each well, a shaker shook for 2 min, followed by standing in a dark place at rt for 10 min, and the relative light unit (RLU) was measured with a Cytation 3 microplate reader.    Click to Show/Hide
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.007 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 5 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	. nM	Negative TROP2 expression (TROP2-)
Method Description	HepG2 at 100uL/well (1000 to 10000 cells), 0.9mg/ml ADCs (10, 3.3, 1.1, 0.37, 0.12, 0.041, 0.014, 0.0046, 0.0015, and 0.00051 nM) were added and incubated for 72 to 120 h, then 100 L of CellTiter Glo reagent was added into each well, a shaker shook for 2 min, followed by standing in a dark place at rt for 10 min, and the relative light unit (RLU) was measured with a Cytation 3 microplate reader.    Click to Show/Hide
In Vitro Model	Hepatoblastoma	HepG2 cells		CVCL_0027
Experiment 2 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.1839 nM	High TROP2 expression (TROP2 +++)
Method Description	FaDu at 100uL/well (1000 to 10000 cells), 0.9mg/ml ADCs (10, 3.3, 1.1, 0.37, 0.12, 0.041, 0.014, 0.0046, 0.0015, and 0.00051 nM) were added and incubated for 72 to 120 h, then 100 L of CellTiter Glo reagent was added into each well, a shaker shook for 2 min, followed by standing in a dark place at rt for 10 min, and the relative light unit (RLU) was measured with a Cytation 3 microplate reader.    Click to Show/Hide
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218
Experiment 3 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.1928 nM	High TROP2 expression (TROP2 +++)
Method Description	BxPC-3 at 100uL/well (1000 to 10000 cells), 0.9mg/ml ADCs (10, 3.3, 1.1, 0.37, 0.12, 0.041, 0.014, 0.0046, 0.0015, and 0.00051 nM) were added and incubated for 72 to 120 h, then 100 L of CellTiter Glo reagent was added into each well, a shaker shook for 2 min, followed by standing in a dark place at rt for 10 min, and the relative light unit (RLU) was measured with a Cytation 3 microplate reader.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 5 Reporting the Activity Date of This ADC					[84]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.004 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.008 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0098 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.01- 1 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H69: 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 13 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	NCI-H69 cells (+NE)		CVCL_1579
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H69: 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 13 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	NCI-H69 cells (-NE)		CVCL_1579
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 21 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (+NE)		CVCL_1600
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 21 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (-NE)		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.01 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-20 was tested in HCC1954,80ul,18&#4524h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.09 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-20 was tested in NCI-N87,80ul,18&#4524h
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.18 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-20 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Emax (TNF-a)	791.6 pg/mL	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-20 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.01&#1770.004 nM	Moderate EREG expression (EREG++)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.02&#1770.009 nM	High EREG expression (EREG +++)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon carcinoma	HCT116 cells		CVCL_0291
Experiment 3 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.14&#1770.16 nM	Moderate EREG expression (EREG++)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	DLD-1 cells		CVCL_0248
Experiment 4 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.31&#1770.05 nM	Low EREG expression (EREG+)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 5 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 nM	Negative EREG expression (EREG-)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	DLD-1 cells (EREG KO)		CVCL_0248
Experiment 6 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 nM	Low EREG expression (EREG+)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SW620 cells		CVCL_0547
Experiment 7 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 nM	Negative EREG expression (EREG-)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon carcinoma	RKO cells		CVCL_0504

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.011 nM	High HER2 expression (HER10 +++)
Method Description	Trastuzumab-C-10 was tested in HCC1954,80ul,18&#4524h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.023 nM	High HER2 expression (HER11 +++)
Method Description	Trastuzumab-C-10 was tested in NCI-N87,80ul,18&#4524h
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	164.13 nM	High HER2 expression (HER12 +++)
Method Description	Trastuzumab-C-10 was tested in NCI-H358,80ul,18&#4524h
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.54 nM	High HER2 expression (HER13 +++)
Method Description	Trastuzumab-C-10 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 5 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Emax (TNF-a)	522.28 pg/mL	High HER2 expression (HER14 +++)
Method Description	Trastuzumab-C-10 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.011 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.011 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.012 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.28 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.013&#451 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.013 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.014 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.35 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.014 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-17 was tested in HCC1954,80ul,18&#4524h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.32 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-17 was tested in NCI-N87,80ul,18&#4524h
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.39 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-17 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Emax (TNF-a)	788.8 pg/mL	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-17 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.014 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.02 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.98 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.017 nM	High HER2 expression (HER15 +++)
Method Description	Trastuzumab-C-11 was tested in NCI-H358,80ul,18&#4524h
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.026 nM	High HER2 expression (HER16 +++)
Method Description	Trastuzumab-C-11 was tested in NCI-H358,80ul,18&#4524h
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	331.62 nM	High HER2 expression (HER17 +++)
Method Description	Trastuzumab-C-11 was tested in NCI-H358,80ul,18&#4524h
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Effective Concentration (EC50)	32.59 nM	High HER2 expression (HER18 +++)
Method Description	Trastuzumab-C-11 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 5 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Emax (TNF-a)	427.95 pg/mL	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-11 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.017 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-15 was tested in HCC1954,80ul,18&#4524h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.17 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-15 was tested in NCI-N87,80ul,18&#4524h
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Effective Concentration (EC50)	74.62 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-15 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Emax (TNF-a)	817.79 pg/mL	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-15 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.018 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-16 was tested in HCC1954,80ul,18&#4524h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.15 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-16 was tested in NCI-N87,80ul,18&#4524h
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.61 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-16 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Emax (TNF-a)	411.5 pg/mL	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-16 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.018 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-21 was tested in HCC1954,80ul,18&#4524h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.12 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-21 was tested in NCI-N87,80ul,18&#4524h
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.13 nM	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-21 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Emax (TNF-a)	573.7 pg/mL	High HER2 expression (HER19 +++)
Method Description	Trastuzumab-C-21 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.018 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.019 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.019 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.019 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.019 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 2 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 6.6 nM
Method Description	The SK-BR-3 cells (ATCC), which are negative for CD30 antigen but positive for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.019 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.025 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.12 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.02 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test). In addition, SK-BR-3
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.02 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.02 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 2 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 6.6 nM
Method Description	The SK-BR-3 cells (ATCC), which are negative for CD30 antigen but positive for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.02 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.021 nM	High HER2 expression (HER5 +++)
Method Description	Trastuzumab-C-9 was tested in NCI-H358,80ul,18&#4524h
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.058 nM	High HER2 expression (HER6 +++)
Method Description	Trastuzumab-C-9 was tested in NCI-H358,80ul,18&#4524h
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	136.77 nM	High HER2 expression (HER7 +++)
Method Description	Trastuzumab-C-9 was tested in NCI-H358,80ul,18&#4524h
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Effective Concentration (EC50)	24.41 nM	High HER2 expression (HER8 +++)
Method Description	Trastuzumab-C-9 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 5 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Emax (TNF-a)	470.23 pg/mL	High HER2 expression (HER9 +++)
Method Description	Trastuzumab-C-9 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.021 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.022 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.022 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.027 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.028 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.029 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.029 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.029 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.03 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.032 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.049 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.85 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.034 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.034 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.034 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.034 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.034 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.036 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.036 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.036 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.036 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.052 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.86 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.038 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.045 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.65 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.038 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.052 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.95 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.038 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.046 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.35 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.039 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.047 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.28 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[90]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.04 nM	High HER2 expression (HER2 +++)
Method Description	1250cells/well for SK-BR-3 (100 uL) of cells were seeded onto 384-well plates and incubated for 24 hours before adding the ADC. After 9 hours, the limited exposure treated plates were removed from the incubator and media containing compound was removed. Cells were washed 2x with growth medium and 40 uL growth medium was then added to each well. Plates were incubated at 37 °C/5% CO, for a further 96 hours. 40uL of CellTiter-Glo reagent was added to each well to be tested (the ratio of CellTiter-Glo reagent to medium was 1:1).the plate was then placed at room temperature for 30 minutes, and then reading was carried out on an EnSpire reader for cell counting.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[90]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.68 nM	High HER2 expression (HER2 +++)
Method Description	1250cells/well for SK-BR-3 (100 uL) of cells were seeded onto 384-well plates and incubated for 24 hours before adding the ADC. After 9 hours, the limited exposure treated plates were removed from the incubator and media containing compound was removed. 40uL of CellTiter-Glo reagent was added to each well to be tested (the ratio of CellTiter-Glo reagent to medium was 1:1).the plate was then placed at room temperature for 30 minutes, and then reading was carried out on an EnSpire reader for cell counting.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[90]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.04 nM	High HER2 expression (HER2 +++)
Method Description	1250cells/well for SK-BR-3 (100 uL) of cells were seeded onto 384-well plates and incubated for 24 hours before adding the ADC. After 9 hours, the limited exposure treated plates were removed from the incubator and media containing compound was removed. Cells were washed 2x with growth medium and 40 uL growth medium was then added to each well. Plates were incubated at 37 °C/5% CO, for a further 96 hours. 40uL of CellTiter-Glo reagent was added to each well to be tested (the ratio of CellTiter-Glo reagent to medium was 1:1).the plate was then placed at room temperature for 30 minutes, and then reading was carried out on an EnSpire reader for cell counting.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[90]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.18 nM	High HER2 expression (HER2 +++)
Method Description	1250cells/well for SK-BR-3 (100 uL) of cells were seeded onto 384-well plates and incubated for 24 hours before adding the ADC. After 9 hours, the limited exposure treated plates were removed from the incubator and media containing compound was removed. 40uL of CellTiter-Glo reagent was added to each well to be tested (the ratio of CellTiter-Glo reagent to medium was 1:1).the plate was then placed at room temperature for 30 minutes, and then reading was carried out on an EnSpire reader for cell counting.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.04 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[91]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.041 nM	High Nectin-4 expression (Nectin-4 +++)
Method Description	Ab1a ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
In Vitro Model	Bladder carcinoma	T24 mScarlet clone 5 nectin-4 negative cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.042 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.043 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.045 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.065 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.85 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.045 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.059 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.86 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.046 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.046 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.046 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[91]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.047 nM	High Nectin-4 expression (Nectin-4 +++)
Method Description	Ab3 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
In Vitro Model	Bladder carcinoma	T24 mScarlet clone 5 nectin-4 negative cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.048 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.065 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.23 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.049 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.058 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.88 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.05 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.05&#1770.14 nM	Low EREG expression (EREG+)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 2 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.06&#1770.048 nM	Moderate EREG expression (EREG++)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 3 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.19&#1770.07 nM	High EREG expression (EREG +++)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon carcinoma	HCT116 cells		CVCL_0291
Experiment 4 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.38&#1770.19 nM	Moderate EREG expression (EREG++)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	DLD-1 cells		CVCL_0248
Experiment 5 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.93&#1772.79 nM	Low EREG expression (EREG+)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SW620 cells		CVCL_0547
Experiment 6 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	31.66&#17724.12 nM	Negative EREG expression (EREG-)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon carcinoma	RKO cells		CVCL_0504
Experiment 7 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 nM	Negative EREG expression (EREG-)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	DLD-1 cells (EREG KO)		CVCL_0248

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.052 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.064 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.72 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.053 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.062 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.95 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.055 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.085 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	12.9 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.058 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.065 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.9 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[91]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0587 nM	High Nectin-4 expression (Nectin-4 +++)
Method Description	Ab6 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
In Vitro Model	Bladder carcinoma	T24 mScarlet clone 5 nectin-4 negative cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.061 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[91]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0627 nM	High Nectin-4 expression (Nectin-4 +++)
Method Description	Ab2 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
In Vitro Model	Bladder carcinoma	T24 mScarlet clone 5 nectin-4 negative cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[91]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0694 nM	High Nectin-4 expression (Nectin-4 +++)
Method Description	Ab8 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
In Vitro Model	Bladder carcinoma	T24 mScarlet clone 5 nectin-4 negative cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[92]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.072 nM	Positive CEACAM6_#84.7 expression (CEACAM6_#84.7 +++/++)
Method Description	In vitro cytotoxicity of ADCs in AsPC-1 cells.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPC-1 cells		CVCL_0152

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.075 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.093 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11.7 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.075 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.082 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.8 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.078 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.095 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.5 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.078 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.098 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.35 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.08 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.095 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11.9 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.08 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.087 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.45 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[91]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.0836 nM	High Nectin-4 expression (Nectin-4 +++)
Method Description	Ab7 ADC was tested in T24 mScarlet clone 5 nectin-4 negative cells ;and with a DAR of 8
In Vitro Model	Bladder carcinoma	T24 mScarlet clone 5 nectin-4 negative cells		CVCL_0554

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.085 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.11 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.9 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.098 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[93]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.1017 nM	High TROP2 expression (TROP2 +++)
Method Description	Cytotoxicity of ADC-2 to BxPC-3 cells
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[93]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.1121 nM	High TROP2 expression (TROP2 +++)
Method Description	Cytotoxicity of ADC to FaDu cells
In Vitro Model	Hypopharyngeal squamous cell carcinoma	FaDu cells		CVCL_1218

Experiment 1 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.106 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.241 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.638 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.108 nM	High HER2 expression (HER2 +++)
Method Description	Trastuzumab-C-7 was tested in HCC1954,80ul,18&#4524h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.293 nM	High HER2 expression (HER2 +++)
Method Description	Trastuzumab-C-7 was tested in NCI-N87,80ul,18&#4524h
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	83.769 nM	High HER2 expression (HER2 +++)
Method Description	Trastuzumab-C-7 was tested in NCI-H358,80ul,18&#4524h
In Vitro Model	Minimally invasive lung adenocarcinoma	NCI-H358 cells		CVCL_1559
Experiment 4 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Half Maximal Effective Concentration (EC50)	11.25 nM	High HER2 expression (HER2 +++)
Method Description	Trastuzumab-C-7 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 5 Reporting the Activity Date of This ADC					[87]
Efficacy Data	Emax (TNF-a)	1791.26 pg/mL	High HER2 expression (HER2 +++)
Method Description	Trastuzumab-C-7 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.114 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[80]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.117 nM	Positive HER2 expression (HER2+++/++)
Method Description	Chemiluminescence staining (Luminescent Cell Viability Assay) was carried out, and IC5owas calculated after reading the fluorescence data.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.12&#1770.002 nM	Moderate EREG expression (EREG++)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.15&#1770.06 nM	High EREG expression (EREG +++)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon carcinoma	HCT116 cells		CVCL_0291
Experiment 3 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.33&#1770.093 nM	Low EREG expression (EREG+)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 4 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.52&#1770.39 nM	Moderate EREG expression (EREG++)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	DLD-1 cells		CVCL_0248
Experiment 5 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 nM	Negative EREG expression (EREG-)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	DLD-1 cells (EREG KO)		CVCL_0248
Experiment 6 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 nM	Low EREG expression (EREG+)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SW620 cells		CVCL_0547
Experiment 7 Reporting the Activity Date of This ADC					[88]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 nM	Negative EREG expression (EREG-)
Method Description	Cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).    Click to Show/Hide
In Vitro Model	Colon carcinoma	RKO cells		CVCL_0504

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.13 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.16 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	69.5 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.135 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.821 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	255.6 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.14 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.14 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.661 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.82 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.18 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.25 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	42.3 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.19 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.35 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.6 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.21 nM
Method Description	The SK-BR-3 cells (ATCC), which are negative for CD30 antigen but positive for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.77 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.23 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.24 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.24 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.25 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.26 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.282 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.43 nM	High TROP2 expression (TROP2 +++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.99 nM	High TROP2 expression (TROP2 +++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	Negative TROP2 expression (TROP2-)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 5 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	124.6 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.3 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.31 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.31 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.31 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.37 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.37 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.37 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.48 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.75 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.37 nM	Positive FR expression (FR+++/++)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	12.005 nM	Negative FR expression (FR-)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.38 nM	High TROP2 expression (TROP2 +++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	17.56 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.39 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.39 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.47 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	24.5 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.41 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.47 nM	Moderate TROP2 expression (TROP2++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.52 nM	High TROP2 expression (TROP2 +++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.47 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.47 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.48 nM	High TROP2 expression (TROP2 +++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.93 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.48 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.49 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.495 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.52 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.56 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.72 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	27.5 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[85]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.588 nM
Method Description	The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.    Click to Show/Hide
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.59 nM	High TROP2 expression (TROP2 +++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.62 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.77 nM	Moderate TROP2 expression (TROP2++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 4 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	31.75 nM	Low TROP2 expression (TROP2+)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Colon adenocarcinoma	Colo205 cells		CVCL_0218
Experiment 5 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	Negative TROP2 expression (TROP2-)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 6 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	Negative TROP2 expression (TROP2-)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.6 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.69 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.8 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.64 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.67 nM	High TROP2 expression (TROP2 +++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.432 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.68 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.75 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	28.9 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.76 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.81 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.85 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	68.3 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.85 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.85 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.95 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.3 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.89 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.07 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	51.8 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.95 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.25 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	52.5 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.95 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.08 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	16.2 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.98 nM	Positive FR expression (FR+++/++)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	37.235 nM	Negative FR expression (FR-)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.17 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.18 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.2 nM	Moderate TROP2 expression (TROP2++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	Negative TROP2 expression (TROP2-)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.23 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.4 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.58 nM	Moderate TROP2 expression (TROP2++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[95]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.79 nM	Positive PSMA expression (PSMA +++/++)
Method Description	In vitro cytotoxicity of anti-PSMA ADCs in human tumour cells expressing PSMAPSMA-positive cell line LNCaP-C4.2
In Vitro Model	Prostate carcinoma	LNCaP-C4.2 cells		CVCL_4782

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.81 nM	Moderate TROP2 expression (TROP2++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	Negative TROP2 expression (TROP2-)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.091 nM	High TROP2 expression (TROP2 +++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	33.75 nM	Positive TROP2 expression (TROP2+++/++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.224 nM	Moderate TROP2 expression (TROP2++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.663 nM	Moderate TROP2 expression (TROP2++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.29 nM	Moderate TROP2 expression (TROP2++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	Negative TROP2 expression (TROP2-)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	Negative TROP2 expression (TROP2-)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.77 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 10%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.25 nM	Positive FR expression (FR+++/++)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	Negative FR expression (FR-)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.366 nM	Moderate TROP2 expression (TROP2++)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	Low TROP2 expression (TROP2+)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Colon adenocarcinoma	Colo205 cells		CVCL_0218
Experiment 3 Reporting the Activity Date of This ADC					[96]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM	Negative TROP2 expression (TROP2-)
Method Description	Table 3 summarizes the results from in vitro cytotoxicity assays in which ADCs containing various DM1 derivative payload at different DARs were tested.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023

Experiment 1 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.37 nM	Positive FR expression (FR+++/++)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.03 nM	Negative FR expression (FR-)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.53 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.73 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.15 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	C4-2B cells		CVCL_4784
Experiment 2 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	12.08 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	PC3-4H7 cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[89]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	336.5 nM
Method Description	MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H69: 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 14 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	NCI-H69 cells (-NE)		CVCL_1579
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H69: 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 14 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	NCI-H69 cells (+NE)		CVCL_1579
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 22 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (+NE)		CVCL_1600
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 22 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (-NE)		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13&#459.9 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13&#459.9 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13&#459.9 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13&#459.9 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13&#459.9 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13.3 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	24.6 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	49.3 nM	Positive HER2 expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	19.47 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.096 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	24.505 nM	Positive FR expression (FR+++/++)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[97]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	36.665 nM	Negative FR expression (FR-)
Method Description	IGROV1 (FRalpha+) and A431 (FRalpha-) cells were sub-cultured and seeded at 10,000 cells/well in complete growth medium in 96 well tissue culture plates, incubated at 37°C, 5% CO2 overnight (16 hours). Test reagents were serial diluted 1:3 in 2 mL deep-well dilution plates, starting at 200 nM (10 dilutions total). Diluted samples (100 uL) were added to the cell plates (starting concentration of test samples at 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 5 days. Medium was then discarded. The plates were washed once with 200 uL DPBS, stained with 50 uL of 0.2% Crystal Violet solution at room temperature for 15 min, and then washed extensively with tap water. Plates were air-dried, and Crystal Violet was dissolved with 200 uL of 1% SDS solution. Plates were read at 570 nm. Data was analyzed using GraphPad Prism 6.    Click to Show/Hide
In Vitro Model	Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma	IGROV1 cells		CVCL_1304

Experiment 1 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	33.1 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well SK-BR-3 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	47.7 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well Calu-3 in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609
Experiment 3 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	85.56 nM	Positive HER2expression (HER2+++/++)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 1000/well NCI-N87 cells in 80 uL media (target positive cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[94]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 400 nM	Negative HER2 expression (HER2-)
Method Description	Cells were seeded in their growth media into 96 well plates (Thermo #136101) one day prior to adding ADCs: 800/well NCI-H1975 cells in 80ul media (target negative cells). 20ul assay media diluted ADC/ isotype conjugates (1:4 10 pts starting from 100uM) as well as free drug were transferred to above cells. The plates were incubated at 37°C, 5% CO2 for 6 days.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511

Experiment 1 Reporting the Activity Date of This ADC					[99]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	36 nM	Moderate CD70 expression (CD70++)
Method Description	Cell Raji were cultured in CO2, thermostatic incubator at 37°C with 5% CO2, in standard conditions. Cells were sub-cultured every 1-2 days, digested with 0.25% trypsin and passaged with a suitable density. When the cells were in the logarithmic growth phase and the amount meeting the assay's demand, cells were collectedand plated onto 96-well solid white flat bottom plates for assay. One day later test articles 2E7-LD038 conjugate ranging from 2 uM to 0.1nM, or extecan ranging from 20 uM to 0.03 nM were added to the cells. Plates were then incubated at 37°C for 96h. Cell Titer Glo (CTG) (40 ul per well) was subsequently added to the plates. Luciferase reading was collected 5min after and analyzed by Microplatereaders. All readings were normalized as percentage of viable cells in the untreated control wells and theICso yalues were calculated by Prism software.    Click to Show/Hide
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC					[99]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	37 nM
Method Description	Cell Caki-1 were cultured in CO2, thermostatic incubator at 37°C with 5% CO2, in standard conditions. Cells were sub-cultured every 1-2 days, digested with 0.25% trypsin and passaged with a suitable density. When the cells were in the logarithmic growth phase and the amount meeting the assay's demand, cells were collectedand plated onto 96-well solid white flat bottom plates for assay. One day later test articles 2E7-LD038 conjugate ranging from 2 uM to 0.1nM, or extecan ranging from 20 uM to 0.03 nM were added to the cells. Plates were then incubated at 37°C for 96h. Cell Titer Glo (CTG) (40 ul per well) was subsequently added to the plates. Luciferase reading was collected 5min after and analyzed by Microplatereaders. All readings were normalized as percentage of viable cells in the untreated control wells and theICso yalues were calculated by Prism software.    Click to Show/Hide
In Vitro Model	Clear cell renal cell carcinoma	Caki-1 cells		CVCL_0234
Experiment 3 Reporting the Activity Date of This ADC					[99]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	292 nM
Method Description	Cell 786-O were cultured in CO2, thermostatic incubator at 37°C with 5% CO2, in standard conditions. Cells were sub-cultured every 1-2 days, digested with 0.25% trypsin and passaged with a suitable density. When the cells were in the logarithmic growth phase and the amount meeting the assay's demand, cells were collectedand plated onto 96-well solid white flat bottom plates for assay. One day later test articles 2E7-LD038 conjugate ranging from 2 uM to 0.1nM, or extecan ranging from 20 uM to 0.03 nM were added to the cells. Plates were then incubated at 37°C for 96h. Cell Titer Glo (CTG) (40 ul per well) was subsequently added to the plates. Luciferase reading was collected 5min after and analyzed by Microplatereaders. All readings were normalized as percentage of viable cells in the untreated control wells and theICso yalues were calculated by Prism software.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	36.9 nM
Method Description	22Rv1 (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC50 results were calculated.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045
Experiment 2 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	40.2 nM
Method Description	SW620 (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC61 results were calculated.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SW620 cells		CVCL_0547
Experiment 3 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	41.64 nM
Method Description	NCI-H820 (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC50 results were calculated.    Click to Show/Hide
In Vitro Model	Lung papillary adenocarcinoma	NCI-H820 cells		CVCL_1592
Experiment 4 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	43.2 nM
Method Description	SK-BR-3 (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC50 results were calculated.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 5 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	55.46 nM
Method Description	OVCAR-8 (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC64 results were calculated.    Click to Show/Hide
In Vitro Model	High grade ovarian serous adenocarcinoma	OVCAR-8 cells		CVCL_1629
Experiment 6 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	70.75 nM
Method Description	HCC827 (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC64 results were calculated.    Click to Show/Hide
In Vitro Model	Lung adenocarcinoma	HCC827 cells		CVCL_2063
Experiment 7 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	93.26 nM
Method Description	LNCaP (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC50 results were calculated.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	LNCaP cells		CVCL_0395

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	66.79 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	69.63 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.7102 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.9334 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[101]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	High C10orf54 expression (C10orf54 +++)
Method Description	C1.18 DBM- (C6)-MMAF was tested in OCI/AML3,100-300nm,3days
In Vitro Model	Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia	OCI/AML3 cells		CVCL_1844
Experiment 2 Reporting the Activity Date of This ADC					[101]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	High C10orf54 expression (C10orf54 +++)
Method Description	C1.18 DBM- (C6)-MMAF was tested in P31/FUJ,100-300nm,3days
In Vitro Model	Acute myeloid leukemia, Childhood acute myeloid leukemia	P31/FUJ cells		CVCL_1632
Experiment 3 Reporting the Activity Date of This ADC					[101]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 100 nM	High C10orf54 expression (C10orf54 +++)
Method Description	C1.18 DBM- (C6)-MMAF was tested in PL21,100-300nm,3days
In Vitro Model	Acute promyelocytic leukemia	PL21 cells		CVCL_2161

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	103&#4599 nM
Method Description	The cells were cultivated according to the standard method using the growth media suggest by provider The test was carried out by detaching the cells with a solution of Accutase in PBS buffer (fromBiochrom AG #L2143).
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI H929 cells		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	105.8 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	115.4 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	112.1 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	118.4 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	174.3 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.275 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	187.3 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4826 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	195.6 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.14 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	229.6 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.7058 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	280.7 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5972 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	293.3 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.8 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	309.2 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	11.67 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	457.6 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	39.79 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 500 nM
Method Description	SW620 (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC62 results were calculated.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	SW620 cells		CVCL_0547
Experiment 2 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 600 nM
Method Description	22Rv1 (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC50 results were calculated.    Click to Show/Hide
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045
Experiment 3 Reporting the Activity Date of This ADC					[100]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1 uM
Method Description	SK-BR-3 (ATCC) cells were selected as the cell line for in vitro activity detection experiments. 2000 cells were inoculated into each well of a 96-well cell culture plate and cultured for 20-24 hours. The antibody-drug conjugate prepared according to the method in Example 3 was formulated with L15 cell culture medium containing 10% FBS into 11 concentration gradients of test solution: 1000, 166.7, 55.6, 18.6, 6.17, 2.06, 0.69, 0.23, 0.08, 0.008 and OnM. 100 ul of the diluted test solution per well was added to the culture plate containing the inoculated cells and incubated in a 37°C, 5% CO, incubator for 144 hours. Then, CellTiter-Glo® Luminescent Cell Viability Assay Reagent (50 ul/well) was added, and the mixture was shaken at 500 rpm at room temperature for 10 minutes. The data were read using a SpectraMaxL microplate reader (OD570nm, with 2-second interval readings), and the IC50 results were calculated.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	550.4 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	244.7 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	706.8 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	787.1 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	731.9 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	735.5 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	865 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	764.3 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	30.24 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	779.4 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.35 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	799.7 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	26.56 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	803.7 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.76 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	834.5 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	365.1 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.83 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4634 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.379 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.54 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.95 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1028 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	15.33 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.12 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.19 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	63.97 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	375 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3765 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.18 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.55 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.68 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.31 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	706 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.24 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.54 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	83.44 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	593 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3022 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.26 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.69 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.6 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	156 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	196 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.26 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.78 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	39.12 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	196 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7636 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.27 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.96 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	180 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	579 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3967 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.29 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.18 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.71 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	69.14 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4970 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.33 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.49 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	15.29 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	21.79 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9174 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.33 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.63 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.56 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	50.18 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3732 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.36 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.86 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.55 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	47.53 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	669 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.38 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.68 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.14 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	16.5 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	106 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.42 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.19 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1266 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.44 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.91 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1601 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.45 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.13 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	114 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	570 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1212 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.45 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.73 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	129 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.51 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.54 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.14 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	21.11 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	714 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 0.51 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.8 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.28 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	14.36 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	60.76 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.56 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11.76 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.19 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	36.77 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4795 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.61 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.63 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13.55 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	27.57 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3082 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.69 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.06 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	31.2 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1340 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.71 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.85 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.16 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	21.18 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	157 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.71 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	12.36 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	530 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2090 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.79 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.45 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.42 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	198 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2797 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.83 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.87 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.72 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	75.39 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	222 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.85 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.63 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.48 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.71 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	122 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 6 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5849 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.95 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.38 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	189 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1226 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5196 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.13 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.82 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.42 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5.15 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	12.21 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 6 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	704 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.14 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.84 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.29 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.74 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11.27 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 6 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	637 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.23 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.48 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.83 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.69 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13.1 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 6 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	932 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 1.52 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.52 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.64 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.58 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	11.51 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	14.75 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.84 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.59 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	16.99 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1711 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8255 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.97 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.16 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.72 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	66.27 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	155 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.55 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	60.81 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 3000 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.63 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	31.21 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 3000 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.98 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.86 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	20.44 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	32.4 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5317 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.58 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.66 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.07 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	13.86 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	189 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4.17 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	61.1 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	134 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 4.65 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.25 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1476 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.29 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.67 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2089 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.59 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.93 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 3000 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	7.91 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	19.33 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 3000 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.53 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing BT474 (breast cancer cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 10 concentrations.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	14.59 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing MDA-MB-361-DYT2 (breast cancer) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	43.5 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing (BT474 (breast cancer), N87 (gastric cancer), MDA-MB-361-DYT2 (breast cancer)) or Her2-non-expressing (MDA-MB-468, HT29) cells, or CD33-target expressing HL60, HEL92.1.7, NB4 or CD33-non-expressing (Raji) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 4 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	749.14 ng/mL	Negative Her2 expression (Her2-)
Method Description	Her2-non-expressing (MDA-MB-468, HT29) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells (HER2-)		CVCL_0419
Experiment 5 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 37021 ng/mL	Negative Her2 expression (Her2-)
Method Description	Her2-non-expressing HT29) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
In Vitro Model	Colon adenocarcinoma	HT29 cells (HER2-)		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.96 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	51.01 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 3000 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	9.71 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	29.08 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	42.58 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	64.65 ng/ml	Positive HER2 expression (HER2+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	578 ng/ml	Negative HER2 expression (HER2-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	10.58 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	29.45 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	618 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	12.05 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	212 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 3000 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	17.64 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	33.52 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	786 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	793 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4320 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	22.17 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	46.04 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	55.05 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	83.68 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	126 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	24.25 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	309 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 3000 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[104]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	34 ng/mL	Positive EDB expression (EDB+++/++)
Method Description	Calculated using four-parameter logistic model #203 with XLfit v4.9 (IDBS)
In Vitro Model	Normal	WI38-VA13 cells		CVCL_2759
Experiment 2 Reporting the Activity Date of This ADC					[104]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3449 ng/mL	Negative EDB expression (EDB-)
Method Description	Calculated using four-parameter logistic model #203 with XLfit v4.10 (IDBS)
In Vitro Model	Colon cancer	HT29 cells		CVCL_A8EZ

Experiment 1 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	51.08 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing BT474 (breast cancer cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 11 concentrations.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	99.02 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing (BT474 (breast cancer), N87 (gastric cancer), MDA-MB-361-DYT2 (breast cancer)) or Her2-non-expressing (MDA-MB-468, HT29) cells, or CD33-target expressing HL60, HEL92.1.7, NB4 or CD33-non-expressing (Raji) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 35 concentrations.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 1588 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing MDA-MB-361-DYT2 (breast cancer) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 35 concentrations.
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 77922 ng/mL	Negative Her2 expression (Her2-)
Method Description	Her2-non-expressing HT29) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
In Vitro Model	Colon adenocarcinoma	HT29 cells (HER2-)		CVCL_0320
Experiment 5 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 77954 ng/mL	Negative Her2 expression (Her2-)
Method Description	Her2-non-expressing (MDA-MB-468, HT29) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 32 concentrations.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells (HER2-)		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	54.33 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	253 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	260 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1171 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	4338 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759

Experiment 1 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	74.59 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing (BT474 (breast cancer), N87 (gastric cancer), MDA-MB-361-DYT2 (breast cancer)) or Her2-non-expressing (MDA-MB-468, HT29) cells, or CD33-target expressing HL60, HEL92.1.7, NB4 or CD33-non-expressing (Raji) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 34 concentrations.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	107.75 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing MDA-MB-361-DYT2 (breast cancer) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 34 concentrations.
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 67340 ng/mL	Negative Her2 expression (Her2-)
Method Description	Her2-non-expressing HT29) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
In Vitro Model	Colon adenocarcinoma	HT29 cells (HER2-)		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	95.87 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	124 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1522 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	96.35 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	161 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	357 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	416 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8031 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	101 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	119 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1095 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	109 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	202 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	227 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	404 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1884 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	112 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	193 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 3000 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	114.74 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing (BT474 (breast cancer), N87 (gastric cancer), MDA-MB-361-DYT2 (breast cancer)) or Her2-non-expressing (MDA-MB-468, HT29) cells, or CD33-target expressing HL60, HEL92.1.7, NB4 or CD33-non-expressing (Raji) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 32 concentrations.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 27368 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing MDA-MB-361-DYT2 (breast cancer) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 32 concentrations.
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 77994 ng/mL	Negative Her2 expression (Her2-)
Method Description	Her2-non-expressing HT29) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
In Vitro Model	Colon adenocarcinoma	HT29 cells (HER2-)		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	146 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	178 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2500 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	227 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	272 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 3000 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005

Experiment 1 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	383.87 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing (BT474 (breast cancer), N87 (gastric cancer), MDA-MB-361-DYT2 (breast cancer)) or Her2-non-expressing (MDA-MB-468, HT29) cells, or CD33-target expressing HL60, HEL92.1.7, NB4 or CD33-non-expressing (Raji) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 36 concentrations.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 78014 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing MDA-MB-361-DYT2 (breast cancer) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 36 concentrations.
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 78014 ng/mL	Negative Her2 expression (Her2-)
Method Description	Her2-non-expressing HT29) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
In Vitro Model	Colon adenocarcinoma	HT29 cells (HER2-)		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	517.63 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing (BT474 (breast cancer), N87 (gastric cancer), MDA-MB-361-DYT2 (breast cancer)) or Her2-non-expressing (MDA-MB-468, HT29) cells, or CD33-target expressing HL60, HEL92.1.7, NB4 or CD33-non-expressing (Raji) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 33 concentrations.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 78019 ng/mL	Positive Her2 expression (Her2+++/++)
Method Description	Her2-Target expressing MDA-MB-361-DYT2 (breast cancer) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 33 concentrations.
In Vitro Model	Breast adenocarcinoma	MDA-MB-361-DYT2 cells		CVCL_0620
Experiment 3 Reporting the Activity Date of This ADC					[103]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 78019 ng/mL	Negative Her2 expression (Her2-)
Method Description	Her2-non-expressing HT29) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
In Vitro Model	Colon adenocarcinoma	HT29 cells (HER2-)		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	756 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA	NB4 cells		CVCL_0005
Experiment 2 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2758 ng/ml	Negative CD33 expression (CD33-)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6368 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation	HL60 cells		CVCL_0002
Experiment 4 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8513 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 5 Reporting the Activity Date of This ADC					[102]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	> 10000 ng/ml	Positive CD33 expression (CD33+++/++)
Method Description	96 hours after treatment, the cell viability was determined by CellTiter 96 aqueous single solution cell proliferation machine translation system analysis
In Vitro Model	Acute erythroid leukemia, Erythroleukemia	HEL92.1.7 cells		CVCL_2481

Experiment 1 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.28 uM	Low HER2 expression (HER2+)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-468 cell.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.36 uM	Low HER2 expression (HER2+)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-231 cell.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.62 uM	Moderate HER2 expression (HER2++)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the BxPc-3 cell.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.4 uM	Low HER2 expression (HER2+)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the AsPc1 cell.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPc1 cells		CVCL_0152
Experiment 5 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.25 uM	Moderate HER2 expression (HER2++)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the CFPAC cell.
In Vitro Model	Cystic fibrosis, Pancreatic ductal adenocarcinoma	CFPAC cells		CVCL_1119

Experiment 1 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.39 uM	Moderate HER2 expression (HER2++)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the BxPc-3 cell.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.39 uM	Low HER2 expression (HER2+)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-468 cell.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 3 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.53 uM	Low HER2 expression (HER2+)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-231 cell.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 4 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2.4 uM	Low HER2 expression (HER2+)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the AsPc1 cell.
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPc1 cells		CVCL_0152
Experiment 5 Reporting the Activity Date of This ADC					[105]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	8.05 uM	Moderate HER2 expression (HER2++)
Method Description	The in vitro antitumor efficacy of ADC was assessed using the CFPAC cell.
In Vitro Model	Cystic fibrosis, Pancreatic ductal adenocarcinoma	CFPAC cells		CVCL_1119

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.016 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.018 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.02 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.026 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.028 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.029 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.03 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.03 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.034 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.538 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[107]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.594 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the effect of the masked ADC - S423 on cell viability after demasking with MMP2 protease, the cytotoxicity of the masked and demasked (MMP2 - treated) ADC - S423 and ADC - S426 was tested on HER2 - positive SK - BR - 3 cells, and compared with that of the naked (unmasked) trastuzumab - based ADC - TRA41C and the isotype - control ADC - RIT41C. After 6 days of treatment, cell viability was measured using the CellTiter - GloTM (CTG) luminescent assay kit.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[107]
Efficacy Data	Half Maximal Effective Concentration (EC50)	82.01 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the effect of the masked ADC - S423 on cell viability after demasking with MMP2 protease, the cytotoxicity of the masked and demasked (MMP2 - treated) ADC - S423 and ADC - S426 was tested on HER2 - positive SK - BR - 3 cells, and compared with that of the naked (unmasked) trastuzumab - based ADC - TRA41C and the isotype - control ADC - RIT41C. After 6 days of treatment, cell viability was measured using the CellTiter - GloTM (CTG) luminescent assay kit.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.594 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[107]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.728 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the effect of the masked ADC - S423 on cell viability after demasking with MMP2 protease, the cytotoxicity of the masked and demasked (MMP2 - treated) ADC - S423 and ADC - S426 was tested on HER2 - positive SK - BR - 3 cells, and compared with that of the naked (unmasked) trastuzumab - based ADC - TRA41C and the isotype - control ADC - RIT41C. After 6 days of treatment, cell viability was measured using the CellTiter - GloTM (CTG) luminescent assay kit.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[107]
Efficacy Data	Half Maximal Effective Concentration (EC50)	324 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	To investigate the effect of the masked ADC - S423 on cell viability after demasking with MMP2 protease, the cytotoxicity of the masked and demasked (MMP2 - treated) ADC - S423 and ADC - S426 was tested on HER2 - positive SK - BR - 3 cells, and compared with that of the naked (unmasked) trastuzumab - based ADC - TRA41C and the isotype - control ADC - RIT41C. After 6 days of treatment, cell viability was measured using the CellTiter - GloTM (CTG) luminescent assay kit.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.728 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	1.17 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[108]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	3.1 ug/ml
Method Description	Conjugates were tested in Pae39324, diluted and loaded into a 96 well polypropylene microtiter plate. Then the microtiter plate was incubated at 37°C overnight.
In Vitro Model	P. aeruginosa strains	Pae39324		.
Experiment 2 Reporting the Activity Date of This ADC					[108]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.3 ug/ml
Method Description	Conjugates were tested in Pae27853, diluted and loaded into a 96 well polypropylene microtiter plate. Then the microtiter plate was incubated at 37°C overnight.
In Vitro Model	P. aeruginosa strains	Pae27853		.

Experiment 1 Reporting the Activity Date of This ADC					[108]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	6.3 ug/ml
Method Description	Conjugates were tested in Pae39324, diluted and loaded into a 96 well polypropylene microtiter plate. Then the microtiter plate was incubated at 37°C overnight.
In Vitro Model	P. aeruginosa strains	Pae39324		.
Experiment 2 Reporting the Activity Date of This ADC					[108]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	25 ug/ml
Method Description	Conjugates were tested in Pae27853, diluted and loaded into a 96 well polypropylene microtiter plate. Then the microtiter plate was incubated at 37°C overnight.
In Vitro Model	P. aeruginosa strains	Pae27853		.

Experiment 1 Reporting the Activity Date of This ADC					[108]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	12.5 ug/ml
Method Description	Conjugates were tested in Pae39324, diluted and loaded into a 96 well polypropylene microtiter plate. Then the microtiter plate was incubated at 37°C overnight.
In Vitro Model	P. aeruginosa strains	Pae39324		.
Experiment 2 Reporting the Activity Date of This ADC					[108]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	25 ug/ml
Method Description	Conjugates were tested in Pae27853, diluted and loaded into a 96 well polypropylene microtiter plate. Then the microtiter plate was incubated at 37°C overnight.
In Vitro Model	P. aeruginosa strains	Pae27853		.

Experiment 1 Reporting the Activity Date of This ADC					[109]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	40- 1.53 × 10 -4 ug/mL	Positive ASCT2 expression (ASCT2+++/++)
Method Description	Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	WiDr cells		CVCL_2760
Experiment 2 Reporting the Activity Date of This ADC					[109]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	80- 3.05 × 10 -4 ug/mL	Positive ASCT2 expression (ASCT2+++/++)
Method Description	Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.    Click to Show/Hide
In Vitro Model	Colon carcinoma	HCT116 cells		CVCL_0291

Experiment 1 Reporting the Activity Date of This ADC					[109]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	40- 1.53 × 10 -4 ug/mL	Positive ASCT2 expression (ASCT2+++/++)
Method Description	Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	WiDr cells		CVCL_2760
Experiment 2 Reporting the Activity Date of This ADC					[109]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	80- 3.05 × 10 -4 ug/mL	Positive ASCT2 expression (ASCT2+++/++)
Method Description	Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.    Click to Show/Hide
In Vitro Model	Colon carcinoma	HCT116 cells		CVCL_0291

Experiment 1 Reporting the Activity Date of This ADC					[109]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	2- 7.62 × 10 -4 g/mL	Positive ASCT2 expression (ASCT2+++/++)
Method Description	Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.    Click to Show/Hide
In Vitro Model	Colon carcinoma	HCT116 cells		CVCL_0291
Experiment 2 Reporting the Activity Date of This ADC					[109]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	30- 1.14 × 10 -4 g/mL	Positive ASCT2 expression (ASCT2+++/++)
Method Description	Target cells were seeded in triplicates into flat-bottom 384-wells plate (400 cells for HCT116 cells). Cells were incubated for 3 to 4 hours at 37°C before addition of an equivalent volume of 2X concentrated ADC or free drug-linker dose range (see table 1 for details). Cells were then incubated into a live cell imaging instrument (Incucyte®) for 6 to 8 days and their confluency was monitored all along the culture.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	WiDr cells		CVCL_2760

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0001 nM	Positive CD45 expression (CD45 +++/++)
Method Description	In vitro PBMC killing assays: ADCs conjugated to AM2
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Cyno PBMC	0.0001 nM	Positive CD45 expression (CD45 +++/++)
Method Description	In vitro PBMC killing assays: ADCs conjugated to AM2
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00122 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00149 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0104 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00183 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.35 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00204 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	3.06 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0028 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.386 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00317 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	4.83 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00466 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00669 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00488 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.158 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00542 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.5 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00724 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0295 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00776 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0671 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00784 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.00904 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.104 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.01013 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0126 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.014 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.6137 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0113 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.372 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0131 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0131 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0823 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.211 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0147 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0182 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.1263 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	4.0737 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0147 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0153 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.1007 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.766 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0151 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.122 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0152 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.358 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0157 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0174 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.1027 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.2807 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0165 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.458 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.603 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0169 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.56 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0172 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0207 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.1341 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	7.6951 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0181 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0184 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.151 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.6273 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 5 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 nM	Low B7H3 expression (B7H3+)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 6 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.9 nM	High B7H3 expression (B7H3 +++)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0205 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.31 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0221 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0221 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.1377 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	27.2295 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0236 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0908 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0239 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.45 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0421 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.251 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0479 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	97.5 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0484 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0499 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	6.84-08 M	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.051 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0512 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.1022 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6 nM	Low B7H3 expression (B7H3+)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 4 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.5 nM	High B7H3 expression (B7H3 +++)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0571 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0621 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	44.9 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0641 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0669 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.175 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0751 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0769 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.116 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0771 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0791 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	500 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0825 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.083 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.348 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.986 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0865 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.4945 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	9.9322 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	100 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0913 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.163 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0915 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0922 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	10.9 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0937 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0953 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.0954 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.1 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	15.4 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.104 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.107 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.1088 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.5115 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	14.9972 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	100 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.109 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.256 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.391 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.109 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.716 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.113 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.122 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.836 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.98 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.123 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.332 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.59 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.127 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.132 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.142 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.957 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.143 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.08 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.11 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.144 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.152 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.719 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.09 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.152 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.6929 nM	High HER2 expression (HER2+++; >300,000 HER2 molecules/cell)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	20.4961 nM	Negative HER2 expression (HER2-)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[112]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	34.0772 nM	Positive HER2 expression (HER2 +++/++)
Method Description	After sample addition, culture for 6 days. Thaw the CellTiter-Glo® reagent and place the cell culture plate at room temperature to equilibrate for 30 minutes. Then add 50 to each well. Shake and lyse the cell plate in a shaker for 2 minutes, then incubate at room temperature for 10 minutes to stabilize the luminescence signal.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.166 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.816 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.43 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.17 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.796 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	5.94 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.182 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.29 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.577 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.187 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.193 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.204 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.584 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.94 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.206 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.23 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.04 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.212 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.16 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.75 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.212 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.213 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.256 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.683 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.218 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	500 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.228 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.684 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	5.08 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.231 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.909 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.4 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.234 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.234 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.236 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.42 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.09 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.241 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	9.19 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.245 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.04 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	3.29 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.247 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	56.9 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.285 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.845 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.16 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.286 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	16.5 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	22.9 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.295 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	500 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.306 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	13.2 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	16.9 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.313 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.566 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.806 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.329 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.346 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.534 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.861 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.375 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.389 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.403 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.433 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.618 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.17 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.441 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.445 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.37 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	9.04 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.467 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.04 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	13 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.481 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.491 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	3.84 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.513 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.517 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.524 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	22.6 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	23.3 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.563 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.61 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.11 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.603 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	500 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.682 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.694 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	6.7 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.736 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.06 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.15 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.816 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.887 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.878 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	4.65 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	9.95 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.15 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	26.6 nM	Positive EGFR expression (EGFR+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.27 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.34 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	15.6 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.34 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	3.07 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.37 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.96 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	> 600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.46 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	80.7 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	> 600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.5 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.92 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.69 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	6 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.72 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.99 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	241 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	1.99 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.54 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	> 600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.09 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.12 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Liver and intrahepatic bile duct epithelial neoplasm	SK-HEP-1 cells		CVCL_0525

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	2.91 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	3.11 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	4.2 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	4.31 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	> 600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	4.42 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	4.71 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	> 600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	> 600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	4.77 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	10.9 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	> 600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[113]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	5.72 nM	Positive XXX expression (XXX+++/++)
Method Description	The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
In Vitro Model	Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary	COV434-AMRH2 cells		CVCL_2010

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	6.52 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	> 600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Lung mucoepidermoid carcinoma	NCI-H292 cells		CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	> 600 nM	Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399

Experiment 1 Reporting the Activity Date of This ADC					[111]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	7.05 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

Experiment 1 Reporting the Activity Date of This ADC					[113]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	37.17 nM	Positive XXX expression (XXX+++/++)
Method Description	The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
In Vitro Model	Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary	COV434-AMRH2 cells		CVCL_2010

Experiment 1 Reporting the Activity Date of This ADC					[113]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	308.55 nM	Positive XXX expression (XXX+++/++)
Method Description	The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
In Vitro Model	Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary	COV434-AMRH2 cells		CVCL_2010

Experiment 1 Reporting the Activity Date of This ADC					[113]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	881.76 nM	Positive XXX expression (XXX+++/++)
Method Description	The cytotoxicity of ADC drugs in COV434-AMRH2 cells.
In Vitro Model	Ovarian small cell carcinoma, hypercalcemic type, Small cell carcinoma of the ovary	COV434-AMRH2 cells		CVCL_2010

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0006 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0023 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro REH cell line killing assay - IC5S0O values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.13 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0037 nM	Positive CD45,Ab7 expression (CD45,Ab7 +++/++)
Method Description	In vitro cell line killing assay - IC52 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.069 nM	Positive CD45,Ab7 expression (CD45,Ab7 +++/++)
Method Description	In vitro REH cell line killing assay - IC5S0O values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	< 0.005 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0055 nM	Positive CD45,Ab2 expression (CD45,Ab2 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0126 nM	Positive CD45,Ab2 expression (CD45,Ab2 +++/++)
Method Description	in vitro HSC PBMC killing assay (stimulated vs non-stimulated) IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 3 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.266 nM	Positive CD45,Ab2 expression (CD45,Ab2 +++/++)
Method Description	in vitro HSC PBMC killing assay (stimulated vs non-stimulated) IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0071 nM	Positive CD45,Ab3 expression (CD45,Ab3 +++/++)
Method Description	In vitro cell line killing assay - IC51 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.048 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro REH cell line killing assay - IC5S0O values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0072 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0085 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0085 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro human and cyno PBMC cell killing assay with Ab5-AM1 - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 3 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.0091 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro human and cyno PBMC cell killing assay with Ab5-AM1 - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 4 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.043 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45+)		CVCL_1650
Experiment 5 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.043 nM	Negative CD45 expression (CD45-)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45-)		CVCL_1650
Experiment 6 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.091 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 7 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.49 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro human and cyno PBMC cell killing assay with Ab5-AM1 - IC50 values
In Vitro Model	Normal	PBMC cells (CD34+CD90+)		CVCL_0140
Experiment 8 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.58 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.01 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.011 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.011 nM	Positive CD45,Ab2 expression (CD45,Ab2 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.015 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.018 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.021 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.022 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.022 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.025 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.066 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45+)		CVCL_1650
Experiment 3 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.066 nM	Negative CD45 expression (CD45-)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45-)		CVCL_1650
Experiment 4 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.2378 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 5 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.38 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.026 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.28 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.027 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.03 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.03 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.04 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.042 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell killing assays: ADCs conjugated to AM1, AM4, or PBD
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 3 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.37 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065
Experiment 4 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.7142 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 5 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	53 nM	Positive CD45,AbA expression (CD45,AbA +++/++)
Method Description	In vitro cell killing assays: ADCs conjugated to AM1, AM4, or PBD
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.042 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.05 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.061 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.083 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.098 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.18 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.25 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	1 nM	Positive CD45,Ab3 expression (CD45,Ab3 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	1.69 nM	Positive CD34+,CD90+ expression (CD34+,CD90+ +++/++)
Method Description	In vitro BM HSC killing assay: ADCs conjugated to AM1 or PBD
In Vitro Model	Bone marrow hematopoietic stem cells	BM HSC cells (CD34+CD90+)		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	3.8 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 3 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	9.624 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 4 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	12 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro cell line killing assays
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	1.9 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	1.98 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	2.1 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	13 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	40 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[79]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	43 nM	Positive CD30 expression (CD30+++/++)
Method Description	Karpas-299 cells (ECACC), which are CD30 antigen-positiveand HER2 antigen-negative,were cultured in RPMI 1640 (GIBCO)containing 30%fetal bovine serum (MP Biomedicals) (hereinafter,referred to as "culture medium A" in this test).
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324

Experiment 1 Reporting the Activity Date of This ADC					[110]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	100 nM	Positive CD45 expression (CD45+++/++)
Method Description	In vitro human and cyno PBMC cell killing assay with Ab5-AM1 - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[114]
Efficacy Data	Half Maximal Effective Concentration (EC50)	92.6 pM
Method Description	The bispecific effect of hOKT3200 on human PBMC killing Raji B tumor cells. The bispecific and calculated EC50 values are shown in the legend.
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[114]
Efficacy Data	Half Maximal Effective Concentration (EC50)	100.3 pM
Method Description	The bispecific effect of hOKT3200 on human PBMC killing RajiB tumor cells. The bispecific and calculated EC50 values are shown in the legend.
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[114]
Efficacy Data	Half Maximal Effective Concentration (EC50)	133.3 pM
Method Description	The bispecific effect of hOKT3200 on human PBMC killing RajiB tumor cells. The bispecific and calculated EC50 values are shown in the legend.
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[114]
Efficacy Data	Half Maximal Effective Concentration (EC50)	741 pM
Method Description	The bispecific effect of hOKT3200 on human PBMC killing RajiB tumor cells. The bispecific and calculated EC50 values are shown in the legend.
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[115]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.005 nM	High uPAR expression (uPAR +++)
Method Description	Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC					[115]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 nM	High uPAR expression (uPAR +++)
Method Description	Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	KPC2 cells		Mus musculus
Experiment 3 Reporting the Activity Date of This ADC					[115]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	High uPAR expression (uPAR +++)
Method Description	Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	KPC1 cells		Mus musculus
Experiment 4 Reporting the Activity Date of This ADC					[115]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 nM	Moderate uPAR expression (uPAR++)
Method Description	Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 5 Reporting the Activity Date of This ADC					[115]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.08 nM	High uPAR expression (uPAR +++)
Method Description	Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	AsPc1 cells		CVCL_0152
Experiment 6 Reporting the Activity Date of This ADC					[115]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 nM	Moderate uPAR expression (uPAR++)
Method Description	Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	MIA PaCa-2 cells		CVCL_0428
Experiment 7 Reporting the Activity Date of This ADC					[115]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12 nM	Negative uPAR expression (uPAR-)
Method Description	Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	KPC2 cells (uPAR KO)		Mus musculus
Experiment 8 Reporting the Activity Date of This ADC					[115]
Efficacy Data	Half Maximal Effective Concentration (EC50)	17 nM	Negative uPAR expression (uPAR-)
Method Description	Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.    Click to Show/Hide
In Vitro Model	Pancreatic ductal adenocarcinoma	KPC1 cells (uPAR KO)		Mus musculus

Experiment 1 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.007 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 2 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.038 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.894 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[117]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[117]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.014 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 3 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.861 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.0101 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.013 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.013 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 2 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.038 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5298 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.015 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 2 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.043 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.042 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.017 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.018 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01807 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on BT474
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02319 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on SKBR3
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03613 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2457 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on HCC1569
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 5 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3206 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6905 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on NCI-N87
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 7 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.9462 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on JIMT-1
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.021 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.022 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.023 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[117]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.023 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[117]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.024 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.024 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 2 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.033 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.647 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.025 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.029 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 3 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.073 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	22 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.025 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 2 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.027 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 3 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.234 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.027 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.028 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.028 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.029 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.034 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 3 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.094 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.07 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.13 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.15 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.39 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.06 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.09 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.15 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.11 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75

Experiment 1 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.033 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Minimally invasive lung adenocarcinoma	H358 cells		CVCL_1559
Experiment 2 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.056 nM	Negative B7H3 expression (B7H3-)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung small cell carcinoma, Small cell lung cancer	H1048 cells		CVCL_1453
Experiment 3 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.511 nM	Positive B7H3 expression (B7H3+++/++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Lung papillary adenocarcinoma	H441 cells		CVCL_1561
Experiment 4 Reporting the Activity Date of This ADC					[116]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	High B7H3 expression (B7H3 +++)
Method Description	Adding the fresh growth-medium containing the varying concentrations of ADCs, 40ul/well into H358, H441, H1048 and MDA-MB-487.
In Vitro Model	Breast adenocarcinoma	MDA-MB-453 cells		CVCL_0418

Experiment 1 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03982 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on BT474
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04299 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on SKBR3
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.09942 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.778 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on HCC1569
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 5 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.413 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419
Experiment 6 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.266 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on JIMT-1
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 7 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13.86 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on NCI-N87
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.06 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.81 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.31 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.12 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159
Experiment 3 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	98.13 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Malignant tumors of the mouse pulmonary system	LLC cells		CVCL_5653

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Pancreatic undifferentiated carcinoma	MiaPaca2 cells		CVCL_0428
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.19 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Lung adenocarcinoma	A549 cells		CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.75 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Normal	HUVEC cells		CVCL_9S75
Experiment 4 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	23.48 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Ovarian serous adenocarcinoma	SKOV-3 cells		CVCL_0532

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.07 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.91 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.09345 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on BT474
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1937 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on SKBR3
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 3 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.8554 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on MCF-7
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 4 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.6 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on HCC1569
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 5 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.47 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on JIMT-1
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 6 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.09 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on MDA-MB-468
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.14 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	6.5 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.15 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.22 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.192 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	870.5 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[121]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.22 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.13 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[121]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.237 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.15 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.29 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	250.7 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26
Experiment 2 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	146.5 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Mouse melanoma	B16F10 cells		CVCL_0159

Experiment 1 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3709 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on NCI-N87
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 2 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.45 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on BT474
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	18.29 nM	High HER3 expression (HER3 +++)
Method Description	A Cell line test on HCC1569
In Vitro Model	Breast ductal carcinoma	HCC1569 cells		CVCL_1255
Experiment 4 Reporting the Activity Date of This ADC					[119]
Efficacy Data	Half Maximal Effective Concentration (EC50)	57.85 nM	Moderate HER3 expression (HER3++)
Method Description	A Cell line test on SKBR3
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3812 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.4 nM	Low B7H3 expression (B7H3+)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 2 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.3 nM	High B7H3 expression (B7H3 +++)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 nM	Low B7H3 expression (B7H3+)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 2 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.9 nM	High B7H3 expression (B7H3 +++)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 nM	Low B7H3 expression (B7H3+)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 2 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.6 nM	High B7H3 expression (B7H3 +++)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[123]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.544 nM	Positive CD19 expression (CD19+++/++)
Method Description	Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model	Adult B acute lymphoblastic leukemia	RS4;11 cells		CVCL_0093
Experiment 2 Reporting the Activity Date of This ADC					[123]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.928 nM	Positive CD19 expression (CD19+++/++)
Method Description	Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model	B-lymphoblastic leukemia	SUP-B15 cells		CVCL_0103
Experiment 3 Reporting the Activity Date of This ADC					[123]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.939 nM	Positive CD19 expression (CD19+++/++)
Method Description	Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC					[123]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.061 nM	Positive CD19 expression (CD19+++/++)
Method Description	Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model	Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma	OCI-LY19 cells		CVCL_1878

Experiment 1 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6 nM	Low B7H3 expression (B7H3+)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 2 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.7 nM	High B7H3 expression (B7H3 +++)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.7 nM	Low B7H3 expression (B7H3+)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 2 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.3 nM	High B7H3 expression (B7H3 +++)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.8 nM	Low B7H3 expression (B7H3+)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 2 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.8 nM	High B7H3 expression (B7H3 +++)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 nM	Low B7H3 expression (B7H3+)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 2 Reporting the Activity Date of This ADC					[122]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.1 nM	High B7H3 expression (B7H3 +++)
Method Description	Cells were seeded (NCI-1650 or MDA-MB-453 (2E3/well) or Capan-1 (4E3/well)) into 3D 96-well plates (Corning: 4520), 80 ul/well, and incubated at 37 °C, 5% CO2, overnight.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[124]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.23 nM	Positive HER expression (HER+++/++)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[124]
Efficacy Data	Half Maximal Effective Concentration (EC50)	75.55 nM	Low HER2 expression (HER2+)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Lung adenocarcinoma	HCC-827 cells		CVCL_2063
Experiment 3 Reporting the Activity Date of This ADC					[124]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.29 ug/mL	Positive HER expression (HER+++/++)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.1 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.8 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.95 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	Ntera-2 cell at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034
Experiment 2 Reporting the Activity Date of This ADC					[118]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	MCF-7 cells at 625 cells/25 pL were seeded in a 384-well plat. ADCs were formulated at 2x starting concentration. Filter sterilized samples were serial diluted (1:3) under sterile conditions and added onto cells in triplicates. For cell viability measurement, 30 microliter of Cell Titer-Glo@ reagent (Promega Corp, Madison, WI) was added into each well, and plates processed as per product instructions.    Click to Show/Hide
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

Experiment 1 Reporting the Activity Date of This ADC					[117]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Negative ROR1 expression (ROR1-)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[117]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10 nM	Positive ROR1 expression (ROR1+++/++)
Method Description	The cell killing EC5o and Span for RORI ADCs conjugated to different linker warheads at different DARs on RORI positive Ntera-2 cell and RORI negative MCF-7 cells
In Vitro Model	Embryonal carcinoma	Ntera-2 cells		CVCL_0034

Experiment 1 Reporting the Activity Date of This ADC					[125]
Efficacy Data	Half Maximal Effective Concentration (EC50)	62 nM
Method Description	Mycloid TNFa Secretion
In Vitro Model	Mycloid	Mycloid cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[125]
Efficacy Data	Half Maximal Effective Concentration (EC50)	68 nM
Method Description	Mycloid TNFa Secretion
In Vitro Model	Mycloid	Mycloid cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[125]
Efficacy Data	Half Maximal Effective Concentration (EC50)	71 nM
Method Description	Mycloid TNFa Secretion
In Vitro Model	Mycloid	Mycloid cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[125]
Efficacy Data	Half Maximal Effective Concentration (EC50)	78 nM
Method Description	Mycloid TNFa Secretion
In Vitro Model	Mycloid	Mycloid cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[121]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 100 nM	Positive HER expression (HER+++/++)
Method Description	In vitro cytotoxicity of the ADCs, isotype control ADCs, and reference free payloads were evaluated using the CellTiter-Glo 2.16 Assay Kit
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[125]
Efficacy Data	Half Maximal Effective Concentration (EC50)	133 nM
Method Description	Mycloid TNFa Secretion
In Vitro Model	Mycloid	Mycloid cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[120]
Efficacy Data	Half Maximal Effective Concentration (EC50)	192.6 nM	Positive TM4SF1 expression (TM4SF1+++/++)
Method Description	Cells were treated incubated for 4 days with the antibody drug conjugate before assessing cell viability on day 5.
In Vitro Model	Sickle cell anemia, Sickle cell disease	MS1 cells		CVCL_YP26

Experiment 1 Reporting the Activity Date of This ADC					[125]
Efficacy Data	Half Maximal Effective Concentration (EC50)	199.5 nM
Method Description	Mycloid TNFa Secretion
In Vitro Model	Mycloid	Mycloid cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[125]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM
Method Description	Mycloid TNFa Secretion
In Vitro Model	Mycloid	Mycloid cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[125]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM
Method Description	Mycloid TNFa Secretion
In Vitro Model	Mycloid	Mycloid cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[125]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM
Method Description	Mycloid TNFa Secretion
In Vitro Model	Mycloid	Mycloid cells		Homo sapiens

Experiment 1 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Positive HER expression (HER+++/++)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[98]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 nM	Negative HER expression (HER-)
Method Description	Using standard cell viability assay, the cytotoxicity and targeting specificity of ADC described in this paper were evaluated for her 2 positive SkBr-3 and her 2 negative MDA-MB-468 cancer cells.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	155 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cF7-5 sort 3A
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cF7-5 sort 3a cells		CVCL_3082
Experiment 2 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	372 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cE8
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cE8 cells		CVCL_3082
Experiment 3 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	2600 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cF7-5 so1t 33
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cF7-5 so1t 33 cells		CVCL_3082
Experiment 4 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	3046 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cE8
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cE8 cells		CVCL_3082
Experiment 5 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	3909 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cF7-5 so1t 33
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cF7-5 so1t 33 cells		CVCL_3082
Experiment 6 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	7487 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cE8
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cE8 cells		CVCL_3082

Experiment 1 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	338 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cF7-5 sort 3A
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cF7-5 sort 3a cells		CVCL_3082
Experiment 2 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	631 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cE8
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cE8 cells		CVCL_3082
Experiment 3 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	2520 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cF7-5 so1t 33
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cF7-5 so1t 33 cells		CVCL_3082
Experiment 4 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	2826 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cE8
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cE8 cells		CVCL_3082
Experiment 5 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	4049 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cF7-5 so1t 33
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cF7-5 so1t 33 cells		CVCL_3082
Experiment 6 Reporting the Activity Date of This ADC
Efficacy Data	Half Maximal Effective Concentration (EC50)	5464 ng/ml	High CLDN18.2 expression (CLDN18.2 +++)
Method Description	A Cell line test on NUGC-4 10cE8
In Vitro Model	Gastric adenocarcinoma	NUGC-4 10cE8 cells		CVCL_3082

Experiment 1 Reporting the Activity Date of This ADC					[124]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ug/mL	Positive HER expression (HER+++/++)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[124]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6 ug/mL	Positive HER expression (HER+++/++)
Method Description	Cell viability was determined after incubation with compound JY201 or JY201b or control.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.19 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.39 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5411 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5411 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5583 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5583 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5715 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5715 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5976 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5976 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6779 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6779 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6779 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.6779 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.7531 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.7531 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.7948 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC					[126]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.7948 ug/ml	High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description	A Cell line test on HEK293T
In Vitro Model	Normal	HEK293T cells		CVCL_0063

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal Effective Concentration (EC50)	14.43 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[106]
Efficacy Data	Half Maximal Effective Concentration (EC50)	27.52 ug/ml	Positive HER2 expression (HER2+++/++)
Method Description	ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	0.01- 1 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 38 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (+NE)		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	0.01- 1 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 38 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (+NE)		CVCL_3422
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 40 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (+NE)		CVCL_1051
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 43 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (+NE)		CVCL_0320
Experiment 5 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 23 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (-NE)		CVCL_0320
Experiment 6 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 38 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (-NE)		CVCL_1600
Experiment 7 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 38 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (-NE)		CVCL_3422
Experiment 8 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	> 1000 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 40 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (-NE)		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	0.01- 1 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 39 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (+NE)		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	0.01- 1 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 39 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (+NE)		CVCL_3422
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 41 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (+NE)		CVCL_1051
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 44 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (+NE)		CVCL_0320
Experiment 5 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 24 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (-NE)		CVCL_0320
Experiment 6 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 39 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (-NE)		CVCL_1600
Experiment 7 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 39 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (-NE)		CVCL_3422
Experiment 8 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	> 1000 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 41 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (-NE)		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	0.01- 1 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 35 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (+NE)		CVCL_3422
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 20 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (-NE)		CVCL_0320
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 40 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (+NE)		CVCL_0320
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 35 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (-NE)		CVCL_1600
Experiment 5 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 35 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (+NE)		CVCL_1600
Experiment 6 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 35 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (-NE)		CVCL_3422
Experiment 7 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 37 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (-NE)		CVCL_1051
Experiment 8 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 37 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (+NE)		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 20 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (+NE)		CVCL_1051
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 20 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (-NE)		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 39 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (+NE)		CVCL_0320
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 34 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (+NE)		CVCL_1600
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 34 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (+NE)		CVCL_3422
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 36 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (-NE)		CVCL_1051
Experiment 5 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 36 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (+NE)		CVCL_1051
Experiment 6 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 34 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (-NE)		CVCL_1600
Experiment 7 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 34 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (-NE)		CVCL_3422
Experiment 8 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	> 1000 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 19 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (-NE)		CVCL_0320

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 10 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (-NE)		CVCL_3422
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 21 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (+NE)		CVCL_1051
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 10 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (-NE)		CVCL_1600
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 10 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (+NE)		CVCL_1600
Experiment 5 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 10 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (+NE)		CVCL_3422
Experiment 6 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 21 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (-NE)		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	1.0- 9.9 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 33 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (+NE)		CVCL_3422
Experiment 2 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 38 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (+NE)		CVCL_0320
Experiment 3 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 33 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (+NE)		CVCL_1600
Experiment 4 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	10- 99 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (SUM149PT 2000 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 33 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Breast inflammatory carcinoma	SUM149PT cells (-NE)		CVCL_3422
Experiment 5 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 35 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (-NE)		CVCL_1051
Experiment 6 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (786-0: 1500 cells/ well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone, whereas to the second set the test compound and 5nM hum.neutrophil elastase were added followed by a 96 h incubation in an incubator at 37°C and 35 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Renal cell carcinoma	786-O cells (+NE)		CVCL_1051
Experiment 7 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (HT29: 1200 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 18 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Colon adenocarcinoma	HT29 cells (-NE)		CVCL_0320
Experiment 8 Reporting the Activity Date of This ADC					[86]
Efficacy Data	Activity Concentration at -50% (AC50)	100- 999 nM
Method Description	After cell counting a defined cell number was sowed into a 96-well culture plate with white bottom (from Costar #3610) (NCI H292: 2500 cells/well) in total volume 100 uL. The cells (except MOLM-13 cells, these cells were directly treated) were then incubated in an incubator at 37°C and 5 % carbon dioxide. After 48 h, the medium was replaced. The treatment started by adding the test compounds in 10 uL of culture medium to the cells in triplicates. Concentrations ranging from 10-5 M to 10-13 M were chosen. Two identical treated sets of samples were prepared. One set was treated with the test compound alone and was added followed by a 96 h incubation in an incubator at 37°C and 33 % carbon dioxide.    Click to Show/Hide
In Vitro Model	Plasma cell myeloma, Multiple myeloma	NCI-H929 cells (-NE)		CVCL_1600

Experiment 1 Reporting the Activity Date of This ADC					[127]
Patients Enrolled	Metastatic breast cancer.
Administration Dosage	1.00 mg/kg.
Related Clinical Trial
NCT Number	NCT05261269	Phase Status	Phase 1
Clinical Description	A dose-escalation study of the safety and pharmacology of dan-222 in subjects with metastatic breast cancer.